




Analysis Type:	PANTHER Overrepresentation Test (Released 20190711)
Annotation Version and Release Date:	Reactome version 65 Released 2019-03-12
Analyzed List:	GCST007847reported.txt (Homo sapiens)	There are duplicate IDs in the file. The unique set of IDs will be used.
Reference List:	Homo sapiens (all genes in database)
Test Type:	FISHER
Correction:	FDR
Reactome pathways	Homo sapiens - REFLIST (20996)	GCST007847reported.txt (110)	GCST007847reported.txt (expected)	GCST007847reported.txt (over/under)	GCST007847reported.txt (fold Enrichment)	GCST007847reported.txt (raw P-value)	GCST007847reported.txt (FDR)
Signaling by FGFR2 fusions (R-HSA-8853333)	1	1	.01	+	 > 100	1.04E-02	1.00E00
FGFR4 mutant receptor activation (R-HSA-1839128)	1	1	.01	+	 > 100	1.04E-02	9.90E-01
Signaling by FGFR2 amplification mutants (R-HSA-2023837)	1	1	.01	+	 > 100	1.04E-02	9.49E-01
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2) (R-HSA-5619073)	1	1	.01	+	 > 100	1.04E-02	9.11E-01
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) (R-HSA-5619107)	3	2	.02	+	 > 100	2.66E-04	1.95E-01
TWIK-related alkaline pH activated K+ channel (TALK) (R-HSA-1299361)	2	1	.01	+	95.44	1.56E-02	1.00E00
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA (R-HSA-428359)	3	1	.02	+	63.62	2.07E-02	1.00E00
betaKlotho-mediated ligand binding (R-HSA-1307965)	3	1	.02	+	63.62	2.07E-02	1.00E00
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation (R-HSA-2892245)	3	1	.02	+	63.62	2.07E-02	1.00E00
TCF7L2 mutants don't bind CTBP (R-HSA-5339700)	3	1	.02	+	63.62	2.07E-02	1.00E00
Regulation of gene expression in early pancreatic precursor cells (R-HSA-210747)	7	2	.04	+	54.54	9.46E-04	3.45E-01
Astrocytic Glutamate-Glutamine Uptake And Metabolism (R-HSA-210455)	4	1	.02	+	47.72	2.58E-02	1.00E00
Neurotransmitter uptake and metabolism In glial cells (R-HSA-112313)	4	1	.02	+	47.72	2.58E-02	1.00E00
CHL1 interactions (R-HSA-447041)	9	2	.05	+	42.42	1.44E-03	4.49E-01
Regulation of gene expression in beta cells (R-HSA-210745)	19	4	.10	+	40.18	5.73E-06	6.28E-03
Activation of RAS in B cells (R-HSA-1169092)	5	1	.03	+	38.17	3.09E-02	1.00E00
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells (R-HSA-210746)	5	1	.03	+	38.17	3.09E-02	1.00E00
IRS activation (R-HSA-74713)	5	1	.03	+	38.17	3.09E-02	1.00E00
Proton-coupled monocarboxylate transport (R-HSA-433692)	6	1	.03	+	31.81	3.59E-02	1.00E00
Repression of WNT target genes (R-HSA-4641265)	12	2	.06	+	31.81	2.35E-03	4.29E-01
Synthesis of Dolichyl-phosphate (R-HSA-446199)	6	1	.03	+	31.81	3.59E-02	1.00E00
Regulation of beta-cell development (R-HSA-186712)	39	6	.20	+	29.37	1.21E-07	2.64E-04
Neurofascin interactions (R-HSA-447043)	7	1	.04	+	27.27	4.09E-02	1.00E00
NrCAM interactions (R-HSA-447038)	7	1	.04	+	27.27	4.09E-02	1.00E00
Reversal of alkylation damage by DNA dioxygenases (R-HSA-73943)	7	1	.04	+	27.27	4.09E-02	1.00E00
Zinc efflux and compartmentalization by the SLC30 family (R-HSA-435368)	7	1	.04	+	27.27	4.09E-02	1.00E00
SHC-related events triggered by IGF1R (R-HSA-2428933)	7	1	.04	+	27.27	4.09E-02	1.00E00
ChREBP activates metabolic gene expression (R-HSA-163765)	7	1	.04	+	27.27	4.09E-02	1.00E00
Binding of TCF/LEF:CTNNB1 to target gene promoters (R-HSA-4411364)	8	1	.04	+	23.86	4.59E-02	1.00E00
DNA Damage Reversal (R-HSA-73942)	8	1	.04	+	23.86	4.59E-02	1.00E00
RUNX3 regulates WNT signaling (R-HSA-8951430)	8	1	.04	+	23.86	4.59E-02	1.00E00
Phase 3 - rapid repolarisation (R-HSA-5576890)	8	1	.04	+	23.86	4.59E-02	1.00E00
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 (R-HSA-8849469)	9	1	.05	+	21.21	5.09E-02	1.00E00
Effects of PIP2 hydrolysis (R-HSA-114508)	27	3	.14	+	21.21	5.05E-04	2.76E-01
Calcineurin activates NFAT (R-HSA-2025928)	9	1	.05	+	21.21	5.09E-02	1.00E00
Signal attenuation (R-HSA-74749)	9	1	.05	+	21.21	5.09E-02	1.00E00
Signaling by FGFR4 in disease (R-HSA-5655291)	10	1	.05	+	19.09	5.59E-02	1.00E00
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) (R-HSA-8877330)	10	1	.05	+	19.09	5.59E-02	1.00E00
CLEC7A (Dectin-1) induces NFAT activation (R-HSA-5607763)	11	1	.06	+	17.35	6.08E-02	1.00E00
Oncogene Induced Senescence (R-HSA-2559585)	33	3	.17	+	17.35	8.68E-04	3.80E-01
CD28 dependent Vav1 pathway (R-HSA-389359)	11	1	.06	+	17.35	6.08E-02	1.00E00
FGFR4 ligand binding and activation (R-HSA-190322)	12	1	.06	+	15.91	6.57E-02	1.00E00
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation (R-HSA-2892247)	12	1	.06	+	15.91	6.57E-02	1.00E00
Tandem pore domain potassium channels (R-HSA-1296346)	12	1	.06	+	15.91	6.57E-02	1.00E00
Phospholipase C-mediated cascade; FGFR4 (R-HSA-5654228)	13	1	.07	+	14.68	7.06E-02	1.00E00
Insulin processing (R-HSA-264876)	27	2	.14	+	14.14	9.97E-03	1.00E00
Negative regulation of FGFR4 signaling (R-HSA-5654733)	27	2	.14	+	14.14	9.97E-03	1.00E00
Regulation of Glucokinase by Glucokinase Regulatory Protein (R-HSA-170822)	28	2	.15	+	13.63	1.06E-02	8.97E-01
Activated point mutants of FGFR2 (R-HSA-2033519)	14	1	.07	+	13.63	7.54E-02	1.00E00
Spry regulation of FGF signaling (R-HSA-1295596)	14	1	.07	+	13.63	7.54E-02	1.00E00
Rap1 signalling (R-HSA-392517)	15	1	.08	+	12.72	8.02E-02	1.00E00
Platelet Adhesion to exposed collagen (R-HSA-75892)	15	1	.08	+	12.72	8.02E-02	1.00E00
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells (R-HSA-210744)	16	1	.08	+	11.93	8.50E-02	1.00E00
SHC-mediated cascade:FGFR4 (R-HSA-5654719)	16	1	.08	+	11.93	8.50E-02	1.00E00
Glucagon-type ligand receptors (R-HSA-420092)	33	2	.17	+	11.57	1.43E-02	1.00E00
Tie2 Signaling (R-HSA-210993)	17	1	.09	+	11.23	8.98E-02	1.00E00
Zinc transporters (R-HSA-435354)	17	1	.09	+	11.23	8.98E-02	1.00E00
PI-3K cascade:FGFR4 (R-HSA-5654720)	17	1	.09	+	11.23	8.98E-02	1.00E00
Signaling by high-kinase activity BRAF mutants (R-HSA-6802948)	36	2	.19	+	10.60	1.67E-02	1.00E00
Synthesis, secretion, and deacylation of Ghrelin (R-HSA-422085)	18	1	.09	+	10.60	9.46E-02	1.00E00
Signaling by FGFR4 (R-HSA-5654743)	36	2	.19	+	10.60	1.67E-02	1.00E00
Other semaphorin interactions (R-HSA-416700)	19	1	.10	+	10.05	9.93E-02	1.00E00
Signaling by FGFR2 IIIa TM (R-HSA-8851708)	19	1	.10	+	10.05	9.93E-02	1.00E00
Nicotinamide salvaging (R-HSA-197264)	19	1	.10	+	10.05	9.93E-02	1.00E00
Signaling by Hippo (R-HSA-2028269)	19	1	.10	+	10.05	9.93E-02	1.00E00
RHO GTPases activate CIT (R-HSA-5625900)	19	1	.10	+	10.05	9.93E-02	1.00E00
FRS-mediated FGFR4 signaling (R-HSA-5654712)	19	1	.10	+	10.05	9.93E-02	1.00E00
Phase 4 - resting membrane potential (R-HSA-5576886)	19	1	.10	+	10.05	9.93E-02	1.00E00
Nuclear Receptor transcription pathway (R-HSA-383280)	39	2	.20	+	9.79	1.93E-02	1.00E00
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) (R-HSA-381771)	20	1	.10	+	9.54	1.04E-01	1.00E00
CTLA4 inhibitory signaling (R-HSA-389513)	20	1	.10	+	9.54	1.04E-01	1.00E00
MAP2K and MAPK activation (R-HSA-5674135)	40	2	.21	+	9.54	2.02E-02	1.00E00
Paradoxical activation of RAF signaling by kinase inactive BRAF (R-HSA-6802955)	40	2	.21	+	9.54	2.02E-02	1.00E00
Signaling by moderate kinase activity BRAF mutants (R-HSA-6802946)	40	2	.21	+	9.54	2.02E-02	1.00E00
Deactivation of the beta-catenin transactivating complex (R-HSA-3769402)	42	2	.22	+	9.09	2.21E-02	1.00E00
G1 Phase (R-HSA-69236)	43	2	.23	+	8.88	2.30E-02	1.00E00
Cyclin D associated events in G1 (R-HSA-69231)	43	2	.23	+	8.88	2.30E-02	1.00E00
Glycolysis (R-HSA-70171)	66	3	.35	+	8.68	5.62E-03	8.21E-01
RAF-independent MAPK1/3 activation (R-HSA-112409)	22	1	.12	+	8.68	1.13E-01	1.00E00
CD28 dependent PI3K/Akt signaling (R-HSA-389357)	22	1	.12	+	8.68	1.13E-01	1.00E00
IRS-related events triggered by IGF1R (R-HSA-2428928)	44	2	.23	+	8.68	2.40E-02	1.00E00
IGF1R signaling cascade (R-HSA-2428924)	44	2	.23	+	8.68	2.40E-02	1.00E00
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) (R-HSA-2404192)	45	2	.24	+	8.48	2.50E-02	1.00E00
Insulin receptor signalling cascade (R-HSA-74751)	46	2	.24	+	8.30	2.60E-02	1.00E00
Negative regulation of FGFR3 signaling (R-HSA-5654732)	23	1	.12	+	8.30	1.18E-01	1.00E00
Downstream signaling of activated FGFR4 (R-HSA-5654716)	23	1	.12	+	8.30	1.18E-01	1.00E00
Incretin synthesis, secretion, and inactivation (R-HSA-400508)	23	1	.12	+	8.30	1.18E-01	1.00E00
Glutamate Neurotransmitter Release Cycle (R-HSA-210500)	23	1	.12	+	8.30	1.18E-01	1.00E00
SUMOylation of intracellular receptors (R-HSA-4090294)	24	1	.13	+	7.95	1.23E-01	1.00E00
EGFR downregulation (R-HSA-182971)	24	1	.13	+	7.95	1.23E-01	1.00E00
WNT ligand biogenesis and trafficking (R-HSA-3238698)	26	1	.14	+	7.34	1.32E-01	1.00E00
Integrin signaling (R-HSA-9006921)	26	1	.14	+	7.34	1.32E-01	1.00E00
Metal ion SLC transporters (R-HSA-425410)	26	1	.14	+	7.34	1.32E-01	1.00E00
Insulin receptor recycling (R-HSA-77387)	26	1	.14	+	7.34	1.32E-01	1.00E00
Negative regulation of FGFR1 signaling (R-HSA-5654726)	26	1	.14	+	7.34	1.32E-01	1.00E00
Integrin alphaIIb beta3 signaling (R-HSA-354192)	26	1	.14	+	7.34	1.32E-01	1.00E00
Signaling by RAS mutants (R-HSA-6802949)	53	2	.28	+	7.20	3.34E-02	1.00E00
Downstream signaling events of B Cell Receptor (BCR) (R-HSA-1168372)	81	3	.42	+	7.07	9.67E-03	1.00E00
XBP1(S) activates chaperone genes (R-HSA-381038)	54	2	.28	+	7.07	3.45E-02	1.00E00
Phase 2 - plateau phase (R-HSA-5576893)	27	1	.14	+	7.07	1.36E-01	1.00E00
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling (R-HSA-6811558)	82	3	.43	+	6.98	9.98E-03	1.00E00
Degradation of beta-catenin by the destruction complex (R-HSA-195253)	82	3	.43	+	6.98	9.98E-03	1.00E00
Constitutive Signaling by Aberrant PI3K in Cancer (R-HSA-2219530)	55	2	.29	+	6.94	3.57E-02	1.00E00
IRE1alpha activates chaperones (R-HSA-381070)	56	2	.29	+	6.82	3.68E-02	1.00E00
Negative regulation of FGFR2 signaling (R-HSA-5654727)	28	1	.15	+	6.82	1.41E-01	1.00E00
Glucose metabolism (R-HSA-70326)	85	3	.45	+	6.74	1.10E-02	8.90E-01
Peptide hormone metabolism (R-HSA-2980736)	86	3	.45	+	6.66	1.13E-02	8.85E-01
Signaling by FGFR in disease (R-HSA-1226099)	58	2	.30	+	6.58	3.92E-02	1.00E00
Negative regulation of the PI3K/AKT network (R-HSA-199418)	89	3	.47	+	6.43	1.24E-02	9.34E-01
FGFR2 mutant receptor activation (R-HSA-1839126)	30	1	.16	+	6.36	1.50E-01	1.00E00
Signaling by BRAF and RAF fusions (R-HSA-6802952)	60	2	.31	+	6.36	4.16E-02	1.00E00
Laminin interactions (R-HSA-3000157)	30	1	.16	+	6.36	1.50E-01	1.00E00
Formation of the beta-catenin:TCF transactivating complex (R-HSA-201722)	60	2	.31	+	6.36	4.16E-02	1.00E00
Nicotinate metabolism (R-HSA-196807)	31	1	.16	+	6.16	1.54E-01	1.00E00
CD28 co-stimulation (R-HSA-389356)	31	1	.16	+	6.16	1.54E-01	1.00E00
Interaction between L1 and Ankyrins (R-HSA-445095)	31	1	.16	+	6.16	1.54E-01	1.00E00
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (R-HSA-2173796)	32	1	.17	+	5.96	1.59E-01	1.00E00
Signaling by FGFR3 (R-HSA-5654741)	33	1	.17	+	5.78	1.63E-01	1.00E00
SLC transporter disorders (R-HSA-5619102)	68	2	.36	+	5.61	5.17E-02	1.00E00
Transcriptional regulation of pluripotent stem cells (R-HSA-452723)	34	1	.18	+	5.61	1.67E-01	1.00E00
Signaling by WNT in cancer (R-HSA-4791275)	34	1	.18	+	5.61	1.67E-01	1.00E00
Signaling by Insulin receptor (R-HSA-74752)	70	2	.37	+	5.45	5.43E-02	1.00E00
Smooth Muscle Contraction (R-HSA-445355)	35	1	.18	+	5.45	1.72E-01	1.00E00
PI3K Cascade (R-HSA-109704)	36	1	.19	+	5.30	1.76E-01	1.00E00
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known (R-HSA-8939243)	36	1	.19	+	5.30	1.76E-01	1.00E00
Fanconi Anemia Pathway (R-HSA-6783310)	38	1	.20	+	5.02	1.85E-01	1.00E00
Oncogenic MAPK signaling (R-HSA-6802957)	76	2	.40	+	5.02	6.26E-02	1.00E00
Platelet Aggregation (Plug Formation) (R-HSA-76009)	38	1	.20	+	5.02	1.85E-01	1.00E00
RAF/MAP kinase cascade (R-HSA-5673001)	230	6	1.20	+	4.98	1.49E-03	3.63E-01
Signaling by FGFR (R-HSA-190236)	77	2	.40	+	4.96	6.40E-02	1.00E00
Synthesis of PA (R-HSA-1483166)	39	1	.20	+	4.89	1.89E-01	1.00E00
Signaling by FGFR2 in disease (R-HSA-5655253)	39	1	.20	+	4.89	1.89E-01	1.00E00
MAPK1/MAPK3 signaling (R-HSA-5684996)	235	6	1.23	+	4.87	1.66E-03	3.31E-01
Senescence-Associated Secretory Phenotype (SASP) (R-HSA-2559582)	79	2	.41	+	4.83	6.69E-02	1.00E00
Negative regulation of MAPK pathway (R-HSA-5675221)	40	1	.21	+	4.77	1.93E-01	1.00E00
IRS-mediated signalling (R-HSA-112399)	40	1	.21	+	4.77	1.93E-01	1.00E00
Class C/3 (Metabotropic glutamate/pheromone receptors) (R-HSA-420499)	40	1	.21	+	4.77	1.93E-01	1.00E00
PI3K/AKT Signaling in Cancer (R-HSA-2219528)	80	2	.42	+	4.77	6.83E-02	1.00E00
Signaling by FGFR1 (R-HSA-5654736)	42	1	.22	+	4.54	2.01E-01	1.00E00
Signaling by EGFR (R-HSA-177929)	42	1	.22	+	4.54	2.01E-01	1.00E00
tRNA modification in the nucleus and cytosol (R-HSA-6782315)	42	1	.22	+	4.54	2.01E-01	1.00E00
Transport of bile salts and organic acids, metal ions and amine compounds (R-HSA-425366)	86	2	.45	+	4.44	7.72E-02	1.00E00
Voltage gated Potassium channels (R-HSA-1296072)	43	1	.23	+	4.44	2.06E-01	1.00E00
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (R-HSA-2173793)	44	1	.23	+	4.34	2.10E-01	1.00E00
NOTCH1 Intracellular Domain Regulates Transcription (R-HSA-2122947)	45	1	.24	+	4.24	2.14E-01	1.00E00
Interleukin-10 signaling (R-HSA-6783783)	45	1	.24	+	4.24	2.14E-01	1.00E00
MAPK family signaling cascades (R-HSA-5683057)	274	6	1.44	+	4.18	3.50E-03	5.48E-01
Oxidative Stress Induced Senescence (R-HSA-2559580)	92	2	.48	+	4.15	8.64E-02	1.00E00
Class B/2 (Secretin family receptors) (R-HSA-373080)	93	2	.49	+	4.10	8.80E-02	1.00E00
Transcriptional regulation by RUNX3 (R-HSA-8878159)	94	2	.49	+	4.06	8.96E-02	1.00E00
Unfolded Protein Response (UPR) (R-HSA-381119)	94	2	.49	+	4.06	8.96E-02	1.00E00
Disorders of transmembrane transporters (R-HSA-5619115)	144	3	.75	+	3.98	4.16E-02	1.00E00
PIP3 activates AKT signaling (R-HSA-1257604)	240	5	1.26	+	3.98	9.23E-03	1.00E00
CLEC7A (Dectin-1) signaling (R-HSA-5607764)	97	2	.51	+	3.94	9.43E-02	1.00E00
Retrograde transport at the Trans-Golgi-Network (R-HSA-6811440)	49	1	.26	+	3.90	2.30E-01	1.00E00
Mitotic G1-G1/S phases (R-HSA-453279)	148	3	.78	+	3.87	4.45E-02	1.00E00
Potassium Channels (R-HSA-1296071)	99	2	.52	+	3.86	9.76E-02	1.00E00
Cross-presentation of soluble exogenous antigens (endosomes) (R-HSA-1236978)	50	1	.26	+	3.82	2.34E-01	1.00E00
Neurotransmitter release cycle (R-HSA-112310)	50	1	.26	+	3.82	2.34E-01	1.00E00
Regulation of activated PAK-2p34 by proteasome mediated degradation (R-HSA-211733)	50	1	.26	+	3.82	2.34E-01	1.00E00
COPI-mediated anterograde transport (R-HSA-6807878)	101	2	.53	+	3.78	1.01E-01	1.00E00
Regulation of ornithine decarboxylase (ODC) (R-HSA-350562)	51	1	.27	+	3.74	2.38E-01	1.00E00
Diseases of signal transduction (R-HSA-5663202)	360	7	1.89	+	3.71	3.12E-03	5.27E-01
Signaling by Non-Receptor Tyrosine Kinases (R-HSA-9006927)	52	1	.27	+	3.67	2.42E-01	1.00E00
Vpu mediated degradation of CD4 (R-HSA-180534)	52	1	.27	+	3.67	2.42E-01	1.00E00
Signaling by PTK6 (R-HSA-8848021)	52	1	.27	+	3.67	2.42E-01	1.00E00
Autodegradation of the E3 ubiquitin ligase COP1 (R-HSA-349425)	52	1	.27	+	3.67	2.42E-01	1.00E00
Ubiquitin-dependent degradation of Cyclin D1 (R-HSA-69229)	52	1	.27	+	3.67	2.42E-01	1.00E00
Ubiquitin-dependent degradation of Cyclin D (R-HSA-75815)	52	1	.27	+	3.67	2.42E-01	1.00E00
G alpha (q) signalling events (R-HSA-416476)	209	4	1.09	+	3.65	2.54E-02	1.00E00
Regulation of Apoptosis (R-HSA-169911)	53	1	.28	+	3.60	2.46E-01	1.00E00
p53-Independent G1/S DNA damage checkpoint (R-HSA-69613)	53	1	.28	+	3.60	2.46E-01	1.00E00
p53-Independent DNA Damage Response (R-HSA-69610)	53	1	.28	+	3.60	2.46E-01	1.00E00
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A (R-HSA-69601)	53	1	.28	+	3.60	2.46E-01	1.00E00
Synthesis of PIPs at the plasma membrane (R-HSA-1660499)	53	1	.28	+	3.60	2.46E-01	1.00E00
Vif-mediated degradation of APOBEC3G (R-HSA-180585)	53	1	.28	+	3.60	2.46E-01	1.00E00
Negative regulation of NOTCH4 signaling (R-HSA-9604323)	53	1	.28	+	3.60	2.46E-01	1.00E00
Cellular Senescence (R-HSA-2559583)	162	3	.85	+	3.53	5.53E-02	1.00E00
Regulation of RUNX3 expression and activity (R-HSA-8941858)	54	1	.28	+	3.53	2.50E-01	1.00E00
AUF1 (hnRNP D0) binds and destabilizes mRNA (R-HSA-450408)	54	1	.28	+	3.53	2.50E-01	1.00E00
Intracellular signaling by second messengers (R-HSA-9006925)	271	5	1.42	+	3.52	1.48E-02	1.00E00
Integration of energy metabolism (R-HSA-163685)	109	2	.57	+	3.50	1.14E-01	1.00E00
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis (R-HSA-8854050)	55	1	.29	+	3.47	2.54E-01	1.00E00
Ion transport by P-type ATPases (R-HSA-936837)	55	1	.29	+	3.47	2.54E-01	1.00E00
SCF-beta-TrCP mediated degradation of Emi1 (R-HSA-174113)	55	1	.29	+	3.47	2.54E-01	1.00E00
Degradation of AXIN (R-HSA-4641257)	55	1	.29	+	3.47	2.54E-01	1.00E00
Stabilization of p53 (R-HSA-69541)	56	1	.29	+	3.41	2.58E-01	1.00E00
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD (R-HSA-5362768)	56	1	.29	+	3.41	2.58E-01	1.00E00
Degradation of DVL (R-HSA-4641258)	57	1	.30	+	3.35	2.62E-01	1.00E00
Signaling by the B Cell Receptor (BCR) (R-HSA-983705)	174	3	.91	+	3.29	6.54E-02	1.00E00
Regulation of PTEN gene transcription (R-HSA-8943724)	59	1	.31	+	3.24	2.69E-01	1.00E00
CDT1 association with the CDC6:ORC:origin complex (R-HSA-68827)	59	1	.31	+	3.24	2.69E-01	1.00E00
L1CAM interactions (R-HSA-373760)	118	2	.62	+	3.24	1.30E-01	1.00E00
Arachidonic acid metabolism (R-HSA-2142753)	59	1	.31	+	3.24	2.69E-01	1.00E00
NIK-->noncanonical NF-kB signaling (R-HSA-5676590)	59	1	.31	+	3.24	2.69E-01	1.00E00
Ca2+ pathway (R-HSA-4086398)	59	1	.31	+	3.24	2.69E-01	1.00E00
Hh mutants abrogate ligand secretion (R-HSA-5387390)	59	1	.31	+	3.24	2.69E-01	1.00E00
Peroxisomal protein import (R-HSA-9033241)	60	1	.31	+	3.18	2.73E-01	1.00E00
Dectin-1 mediated noncanonical NF-kB signaling (R-HSA-5607761)	60	1	.31	+	3.18	2.73E-01	1.00E00
SCF(Skp2)-mediated degradation of p27/p21 (R-HSA-187577)	60	1	.31	+	3.18	2.73E-01	1.00E00
GLI3 is processed to GLI3R by the proteasome (R-HSA-5610785)	60	1	.31	+	3.18	2.73E-01	1.00E00
Degradation of GLI2 by the proteasome (R-HSA-5610783)	60	1	.31	+	3.18	2.73E-01	1.00E00
Degradation of GLI1 by the proteasome (R-HSA-5610780)	60	1	.31	+	3.18	2.73E-01	1.00E00
Defective CFTR causes cystic fibrosis (R-HSA-5678895)	61	1	.32	+	3.13	2.77E-01	1.00E00
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) (R-HSA-381426)	124	2	.65	+	3.08	1.40E-01	1.00E00
Fc epsilon receptor (FCERI) signaling (R-HSA-2454202)	189	3	.99	+	3.03	7.91E-02	1.00E00
Synthesis of substrates in N-glycan biosythesis (R-HSA-446219)	63	1	.33	+	3.03	2.85E-01	1.00E00
Autodegradation of Cdh1 by Cdh1:APC/C (R-HSA-174084)	63	1	.33	+	3.03	2.85E-01	1.00E00
Semaphorin interactions (R-HSA-373755)	64	1	.34	+	2.98	2.88E-01	1.00E00
Asymmetric localization of PCP proteins (R-HSA-4608870)	64	1	.34	+	2.98	2.88E-01	1.00E00
Platelet activation, signaling and aggregation (R-HSA-76002)	259	4	1.36	+	2.95	4.89E-02	1.00E00
p53-Dependent G1/S DNA damage checkpoint (R-HSA-69580)	65	1	.34	+	2.94	2.92E-01	1.00E00
p53-Dependent G1 DNA Damage Response (R-HSA-69563)	65	1	.34	+	2.94	2.92E-01	1.00E00
Hedgehog ligand biogenesis (R-HSA-5358346)	65	1	.34	+	2.94	2.92E-01	1.00E00
Mitochondrial protein import (R-HSA-1268020)	65	1	.34	+	2.94	2.92E-01	1.00E00
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha (R-HSA-1234176)	66	1	.35	+	2.89	2.96E-01	1.00E00
Signaling by FGFR2 (R-HSA-5654738)	66	1	.35	+	2.89	2.96E-01	1.00E00
G1/S DNA Damage Checkpoints (R-HSA-69615)	67	1	.35	+	2.85	2.99E-01	1.00E00
Activation of NF-kappaB in B cells (R-HSA-1169091)	67	1	.35	+	2.85	2.99E-01	1.00E00
APC/C:Cdc20 mediated degradation of Securin (R-HSA-174154)	67	1	.35	+	2.85	2.99E-01	1.00E00
TCF dependent signaling in response to WNT (R-HSA-201681)	202	3	1.06	+	2.83	9.19E-02	1.00E00
Assembly of the pre-replicative complex (R-HSA-68867)	68	1	.36	+	2.81	3.03E-01	1.00E00
Muscle contraction (R-HSA-397014)	204	3	1.07	+	2.81	9.40E-02	1.00E00
Regulation of RAS by GAPs (R-HSA-5658442)	68	1	.36	+	2.81	3.03E-01	1.00E00
Ub-specific processing proteases (R-HSA-5689880)	205	3	1.07	+	2.79	9.50E-02	1.00E00
Transcriptional regulation by RUNX1 (R-HSA-8878171)	205	3	1.07	+	2.79	9.50E-02	1.00E00
PTEN Regulation (R-HSA-6807070)	138	2	.72	+	2.77	1.66E-01	1.00E00
Regulation of PTEN stability and activity (R-HSA-8948751)	69	1	.36	+	2.77	3.07E-01	1.00E00
Costimulation by the CD28 family (R-HSA-388841)	69	1	.36	+	2.77	3.07E-01	1.00E00
Cardiac conduction (R-HSA-5576891)	139	2	.73	+	2.75	1.67E-01	1.00E00
Amyloid fiber formation (R-HSA-977225)	70	1	.37	+	2.73	3.10E-01	1.00E00
C-type lectin receptors (CLRs) (R-HSA-5621481)	140	2	.73	+	2.73	1.69E-01	1.00E00
Regulation of RUNX2 expression and activity (R-HSA-8939902)	71	1	.37	+	2.69	3.14E-01	1.00E00
Signaling by NOTCH1 (R-HSA-1980143)	71	1	.37	+	2.69	3.14E-01	1.00E00
FCERI mediated NF-kB activation (R-HSA-2871837)	142	2	.74	+	2.69	1.73E-01	1.00E00
Orc1 removal from chromatin (R-HSA-68949)	71	1	.37	+	2.69	3.14E-01	1.00E00
Beta-catenin independent WNT signaling (R-HSA-3858494)	143	2	.75	+	2.67	1.75E-01	1.00E00
Signaling by TGF-beta Receptor Complex (R-HSA-170834)	72	1	.38	+	2.65	3.18E-01	1.00E00
CDK-mediated phosphorylation and removal of Cdc6 (R-HSA-69017)	72	1	.38	+	2.65	3.18E-01	1.00E00
Cdc20:Phospho-APC/C mediated degradation of Cyclin A (R-HSA-174184)	72	1	.38	+	2.65	3.18E-01	1.00E00
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 (R-HSA-174178)	72	1	.38	+	2.65	3.18E-01	1.00E00
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint (R-HSA-179419)	73	1	.38	+	2.61	3.21E-01	1.00E00
Signaling by WNT (R-HSA-195721)	297	4	1.56	+	2.57	7.27E-02	1.00E00
APC/C:Cdc20 mediated degradation of mitotic proteins (R-HSA-176409)	75	1	.39	+	2.54	3.28E-01	1.00E00
Regulation of Hypoxia-inducible Factor (HIF) by oxygen (R-HSA-1234174)	75	1	.39	+	2.54	3.28E-01	1.00E00
Cellular response to hypoxia (R-HSA-2262749)	75	1	.39	+	2.54	3.28E-01	1.00E00
ABC transporter disorders (R-HSA-5619084)	76	1	.40	+	2.51	3.32E-01	1.00E00
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins (R-HSA-176814)	76	1	.40	+	2.51	3.32E-01	1.00E00
ER to Golgi Anterograde Transport (R-HSA-199977)	154	2	.81	+	2.48	1.95E-01	1.00E00
Antigen processing: Ubiquitination & Proteasome degradation (R-HSA-983168)	309	4	1.62	+	2.47	8.12E-02	1.00E00
The role of GTSE1 in G2/M progression after G2 checkpoint (R-HSA-8852276)	78	1	.41	+	2.45	3.39E-01	1.00E00
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein (R-HSA-446193)	78	1	.41	+	2.45	3.39E-01	1.00E00
Regulation of APC/C activators between G1/S and early anaphase (R-HSA-176408)	80	1	.42	+	2.39	3.46E-01	1.00E00
Regulation of insulin secretion (R-HSA-422356)	80	1	.42	+	2.39	3.46E-01	1.00E00
SLC-mediated transmembrane transport (R-HSA-425407)	243	3	1.27	+	2.36	1.37E-01	1.00E00
Signaling by NOTCH4 (R-HSA-9013694)	81	1	.42	+	2.36	3.49E-01	1.00E00
Transcriptional regulation of white adipocyte differentiation (R-HSA-381340)	83	1	.43	+	2.30	3.56E-01	1.00E00
Cyclin E associated events during G1/S transition  (R-HSA-69202)	83	1	.43	+	2.30	3.56E-01	1.00E00
PI Metabolism (R-HSA-1483255)	84	1	.44	+	2.27	3.59E-01	1.00E00
Integrin cell surface interactions (R-HSA-216083)	84	1	.44	+	2.27	3.59E-01	1.00E00
ER-Phagosome pathway (R-HSA-1236974)	84	1	.44	+	2.27	3.59E-01	1.00E00
Metabolism of polyamines (R-HSA-351202)	84	1	.44	+	2.27	3.59E-01	1.00E00
DNA Replication Pre-Initiation (R-HSA-69002)	85	1	.45	+	2.25	3.63E-01	1.00E00
Cyclin A:Cdk2-associated events at S phase entry (R-HSA-69656)	85	1	.45	+	2.25	3.63E-01	1.00E00
M/G1 Transition (R-HSA-68874)	85	1	.45	+	2.25	3.63E-01	1.00E00
Hedgehog 'on' state (R-HSA-5632684)	85	1	.45	+	2.25	3.63E-01	1.00E00
Regulation of mRNA stability by proteins that bind AU-rich elements (R-HSA-450531)	86	1	.45	+	2.22	3.66E-01	1.00E00
APC/C-mediated degradation of cell cycle proteins (R-HSA-174143)	86	1	.45	+	2.22	3.66E-01	1.00E00
Regulation of mitotic cell cycle (R-HSA-453276)	86	1	.45	+	2.22	3.66E-01	1.00E00
Metabolism of carbohydrates (R-HSA-71387)	266	3	1.39	+	2.15	1.66E-01	1.00E00
Viral mRNA Translation (R-HSA-192823)	89	1	.47	+	2.14	3.76E-01	1.00E00
MAPK6/MAPK4 signaling (R-HSA-5687128)	89	1	.47	+	2.14	3.76E-01	1.00E00
FCERI mediated Ca+2 mobilization (R-HSA-2871809)	89	1	.47	+	2.14	3.76E-01	1.00E00
Switching of origins to a post-replicative state (R-HSA-69052)	90	1	.47	+	2.12	3.79E-01	1.00E00
GPCR ligand binding (R-HSA-500792)	454	5	2.38	+	2.10	9.22E-02	1.00E00
PCP/CE pathway (R-HSA-4086400)	92	1	.48	+	2.07	3.86E-01	1.00E00
Transport to the Golgi and subsequent modification (R-HSA-948021)	185	2	.97	+	2.06	2.55E-01	1.00E00
Peptide ligand-binding receptors (R-HSA-375276)	186	2	.97	+	2.05	2.57E-01	1.00E00
Post-translational modification: synthesis of GPI-anchored proteins (R-HSA-163125)	93	1	.49	+	2.05	3.89E-01	1.00E00
Class I MHC mediated antigen processing & presentation (R-HSA-983169)	372	4	1.95	+	2.05	1.34E-01	1.00E00
Deubiquitination (R-HSA-5688426)	282	3	1.48	+	2.03	1.86E-01	1.00E00
Developmental Biology (R-HSA-1266738)	1038	11	5.44	+	2.02	2.45E-02	1.00E00
UCH proteinases (R-HSA-5689603)	96	1	.50	+	1.99	3.98E-01	1.00E00
Cellular responses to stress (R-HSA-2262752)	393	4	2.06	+	1.94	1.53E-01	1.00E00
RUNX1 regulates transcription of genes involved in differentiation of HSCs (R-HSA-8939236)	99	1	.52	+	1.93	4.08E-01	1.00E00
Antigen processing-Cross presentation (R-HSA-1236975)	100	1	.52	+	1.91	4.11E-01	1.00E00
Downstream TCR signaling (R-HSA-202424)	100	1	.52	+	1.91	4.11E-01	1.00E00
TNFR2 non-canonical NF-kB pathway (R-HSA-5668541)	100	1	.52	+	1.91	4.11E-01	1.00E00
Signaling by NOTCH (R-HSA-157118)	201	2	1.05	+	1.90	2.86E-01	1.00E00
Signaling by TGF-beta family members (R-HSA-9006936)	101	1	.53	+	1.89	4.14E-01	1.00E00
Interleukin-1 signaling (R-HSA-9020702)	101	1	.53	+	1.89	4.14E-01	1.00E00
Asparagine N-linked glycosylation (R-HSA-446203)	304	3	1.59	+	1.88	2.16E-01	1.00E00
tRNA processing (R-HSA-72306)	102	1	.53	+	1.87	4.17E-01	1.00E00
Disease (R-HSA-1643685)	1023	10	5.36	+	1.87	6.96E-02	1.00E00
Signal Transduction (R-HSA-162582)	2667	26	13.97	+	1.86	1.46E-03	3.99E-01
ABC-family proteins mediated transport (R-HSA-382556)	103	1	.54	+	1.85	4.20E-01	1.00E00
Transport of inorganic cations/anions and amino acids/oligopeptides (R-HSA-425393)	105	1	.55	+	1.82	4.26E-01	1.00E00
Phospholipid metabolism (R-HSA-1483257)	212	2	1.11	+	1.80	3.07E-01	1.00E00
Post-translational protein phosphorylation (R-HSA-8957275)	107	1	.56	+	1.78	4.32E-01	1.00E00
Signaling by Receptor Tyrosine Kinases (R-HSA-9006934)	440	4	2.31	+	1.74	2.97E-01	1.00E00
Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807)	111	1	.58	+	1.72	4.44E-01	1.00E00
Hemostasis (R-HSA-109582)	671	6	3.52	+	1.71	1.70E-01	1.00E00
Hedgehog 'off' state (R-HSA-5610787)	112	1	.59	+	1.70	4.47E-01	1.00E00
SRP-dependent cotranslational protein targeting to membrane (R-HSA-1799339)	112	1	.59	+	1.70	4.47E-01	1.00E00
PPARA activates gene expression (R-HSA-1989781)	114	1	.60	+	1.67	4.53E-01	1.00E00
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) (R-HSA-400206)	115	1	.60	+	1.66	4.55E-01	1.00E00
Adaptive Immune System (R-HSA-1280218)	818	7	4.29	+	1.63	2.07E-01	1.00E00
Neddylation (R-HSA-8951664)	234	2	1.23	+	1.63	3.49E-01	1.00E00
Cellular responses to external stimuli (R-HSA-8953897)	470	4	2.46	+	1.62	3.16E-01	1.00E00
Transcriptional regulation by RUNX2 (R-HSA-8878166)	118	1	.62	+	1.62	4.64E-01	1.00E00
Synthesis of DNA (R-HSA-69239)	119	1	.62	+	1.60	4.67E-01	1.00E00
Metabolism of water-soluble vitamins and cofactors (R-HSA-196849)	120	1	.63	+	1.59	4.70E-01	1.00E00
Neuronal System (R-HSA-112316)	361	3	1.89	+	1.59	4.42E-01	1.00E00
TCR signaling (R-HSA-202403)	121	1	.63	+	1.58	4.72E-01	1.00E00
Host Interactions of HIV factors (R-HSA-162909)	125	1	.65	+	1.53	4.83E-01	1.00E00
GPCR downstream signalling (R-HSA-388396)	1138	9	5.96	+	1.51	2.02E-01	1.00E00
DNA Replication (R-HSA-69306)	127	1	.67	+	1.50	4.89E-01	1.00E00
Platelet degranulation  (R-HSA-114608)	127	1	.67	+	1.50	4.89E-01	1.00E00
Glycerophospholipid biosynthesis (R-HSA-1483206)	129	1	.68	+	1.48	4.94E-01	1.00E00
G alpha (i) signalling events (R-HSA-418594)	392	3	2.05	+	1.46	4.64E-01	1.00E00
G1/S Transition (R-HSA-69206)	131	1	.69	+	1.46	4.99E-01	1.00E00
Influenza Viral RNA Transcription and Replication (R-HSA-168273)	131	1	.69	+	1.46	4.99E-01	1.00E00
Response to elevated platelet cytosolic Ca2+ (R-HSA-76005)	132	1	.69	+	1.45	5.02E-01	1.00E00
Signaling by GPCR (R-HSA-372790)	1198	9	6.28	+	1.43	2.97E-01	1.00E00
Generic Transcription Pathway (R-HSA-212436)	1094	8	5.73	+	1.40	2.85E-01	1.00E00
Interleukin-1 family signaling (R-HSA-446652)	137	1	.72	+	1.39	5.15E-01	1.00E00
Metabolism of proteins (R-HSA-392499)	2078	15	10.89	+	1.38	1.99E-01	1.00E00
Post-translational protein modification (R-HSA-597592)	1390	10	7.28	+	1.37	3.32E-01	1.00E00
Rho GTPase cycle (R-HSA-194840)	140	1	.73	+	1.36	5.23E-01	1.00E00
Influenza Life Cycle (R-HSA-168255)	140	1	.73	+	1.36	5.23E-01	1.00E00
Transport of small molecules (R-HSA-382551)	716	5	3.75	+	1.33	4.29E-01	1.00E00
DNA Repair (R-HSA-73894)	293	2	1.54	+	1.30	6.68E-01	1.00E00
Signaling by Hedgehog (R-HSA-5358351)	148	1	.78	+	1.29	5.42E-01	1.00E00
Signaling by Interleukins (R-HSA-449147)	449	3	2.35	+	1.28	5.12E-01	1.00E00
G2/M Checkpoints (R-HSA-69481)	151	1	.79	+	1.26	5.49E-01	1.00E00
Influenza Infection (R-HSA-168254)	151	1	.79	+	1.26	5.49E-01	1.00E00
RNA Polymerase II Transcription (R-HSA-73857)	1216	8	6.37	+	1.26	5.35E-01	1.00E00
SUMO E3 ligases SUMOylate target proteins (R-HSA-3108232)	156	1	.82	+	1.22	5.61E-01	1.00E00
Class A/1 (Rhodopsin-like receptors) (R-HSA-373076)	321	2	1.68	+	1.19	6.86E-01	1.00E00
S Phase (R-HSA-69242)	161	1	.84	+	1.19	5.72E-01	1.00E00
SUMOylation (R-HSA-2990846)	162	1	.85	+	1.18	5.75E-01	1.00E00
Cell Cycle, Mitotic (R-HSA-69278)	495	3	2.59	+	1.16	7.46E-01	1.00E00
Apoptosis (R-HSA-109581)	165	1	.86	+	1.16	5.81E-01	1.00E00
Programmed Cell Death (R-HSA-5357801)	168	1	.88	+	1.14	5.88E-01	1.00E00
Gene expression (Transcription) (R-HSA-74160)	1351	8	7.08	+	1.13	6.95E-01	1.00E00
Regulation of expression of SLITs and ROBOs (R-HSA-9010553)	170	1	.89	+	1.12	5.92E-01	1.00E00
Fatty acid metabolism (R-HSA-8978868)	174	1	.91	+	1.10	6.01E-01	1.00E00
Metabolism of lipids (R-HSA-556833)	731	4	3.83	+	1.04	7.94E-01	1.00E00
Ion channel transport (R-HSA-983712)	183	1	.96	+	1.04	6.19E-01	1.00E00
Axon guidance (R-HSA-422475)	550	3	2.88	+	1.04	7.66E-01	1.00E00
Infectious disease (R-HSA-5663205)	370	2	1.94	+	1.03	7.21E-01	1.00E00
Metabolism of vitamins and cofactors (R-HSA-196854)	186	1	.97	+	1.03	6.25E-01	1.00E00
Separation of Sister Chromatids (R-HSA-2467813)	186	1	.97	+	1.03	6.25E-01	1.00E00
Metabolism (R-HSA-1430728)	2061	11	10.80	+	1.02	8.73E-01	1.00E00
G alpha (s) signalling events (R-HSA-418555)	575	3	3.01	-	1.00	1.00E00	1.00E00
Mitotic Anaphase (R-HSA-68882)	194	1	1.02	-	.98	1.00E00	1.00E00
Mitotic Metaphase and Anaphase (R-HSA-2555396)	195	1	1.02	-	.98	1.00E00	1.00E00
G2/M Transition (R-HSA-69275)	195	1	1.02	-	.98	1.00E00	1.00E00
Mitotic G2-G2/M phases (R-HSA-453274)	197	1	1.03	-	.97	1.00E00	1.00E00
Cell surface interactions at the vascular wall (R-HSA-202733)	198	1	1.04	-	.96	1.00E00	1.00E00
Cell Cycle (R-HSA-1640170)	600	3	3.14	-	.95	1.00E00	1.00E00
Intra-Golgi and retrograde Golgi-to-ER traffic (R-HSA-6811442)	202	1	1.06	-	.94	1.00E00	1.00E00
Signaling by Rho GTPases (R-HSA-194315)	408	2	2.14	-	.94	1.00E00	1.00E00
Membrane Trafficking (R-HSA-199991)	621	3	3.25	-	.92	1.00E00	1.00E00
Signaling by ROBO receptors (R-HSA-376176)	216	1	1.13	-	.88	1.00E00	1.00E00
Transmission across Chemical Synapses (R-HSA-112315)	218	1	1.14	-	.88	1.00E00	1.00E00
Metabolism of RNA (R-HSA-8953854)	660	3	3.46	-	.87	1.00E00	1.00E00
Cytokine Signaling in Immune system (R-HSA-1280215)	669	3	3.50	-	.86	1.00E00	1.00E00
HIV Infection (R-HSA-162906)	228	1	1.19	-	.84	1.00E00	1.00E00
Vesicle-mediated transport (R-HSA-5653656)	720	3	3.77	-	.80	1.00E00	1.00E00
Immune System (R-HSA-168256)	2035	8	10.66	-	.75	5.16E-01	1.00E00
Cell Cycle Checkpoints (R-HSA-69620)	271	1	1.42	-	.70	1.00E00	1.00E00
Unclassified (UNCLASSIFIED)	10452	38	54.76	-	.69	1.52E-03	3.34E-01
RHO GTPase Effectors (R-HSA-195258)	278	1	1.46	-	.69	1.00E00	1.00E00
Translation (R-HSA-72766)	293	1	1.54	-	.65	1.00E00	1.00E00
Extracellular matrix organization (R-HSA-1474244)	299	1	1.57	-	.64	1.00E00	1.00E00
M Phase (R-HSA-68886)	353	1	1.85	-	.54	1.00E00	1.00E00
Metabolism of amino acids and derivatives (R-HSA-71291)	365	1	1.91	-	.52	1.00E00	1.00E00
Innate Immune System (R-HSA-168249)	1102	3	5.77	-	.52	3.85E-01	1.00E00
Neutrophil degranulation (R-HSA-6798695)	479	1	2.51	-	.40	5.24E-01	1.00E00
PI-3K cascade:FGFR1 (R-HSA-5654689)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
SHC-mediated cascade:FGFR1 (R-HSA-5654688)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Downstream signaling of activated FGFR1 (R-HSA-5654687)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Uptake and function of diphtheria toxin (R-HSA-5336415)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Mitochondrial translation elongation (R-HSA-5389840)	88	0	.46	-	 < 0.01	1.00E00	1.00E00
APC truncation mutants have impaired AXIN binding (R-HSA-5467337)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
MyD88:Mal cascade initiated on plasma membrane (R-HSA-166058)	94	0	.49	-	 < 0.01	1.00E00	1.00E00
APC truncation mutants are not K63 polyubiquitinated (R-HSA-5467333)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Branched-chain amino acid catabolism (R-HSA-70895)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Formation of the Editosome (R-HSA-75094)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
GTP hydrolysis and joining of the 60S ribosomal subunit (R-HSA-72706)	112	0	.59	-	 < 0.01	1.00E00	1.00E00
Peptide hormone biosynthesis (R-HSA-209952)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
MAP kinase activation (R-HSA-450294)	63	0	.33	-	 < 0.01	1.00E00	1.00E00
Ribosomal scanning and start codon recognition (R-HSA-72702)	58	0	.30	-	 < 0.01	1.00E00	1.00E00
Defective ABCC2 causes Dubin-Johnson syndrome (R-HSA-5679001)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Detoxification of Reactive Oxygen Species (R-HSA-3299685)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Alpha-oxidation of phytanate (R-HSA-389599)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Activated NTRK2 signals through FYN (R-HSA-9032500)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Diseases of Mismatch Repair (MMR) (R-HSA-5423599)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of aspirin-triggered D-series resolvins (R-HSA-9020265)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Platelet calcium homeostasis (R-HSA-418360)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
DAG and IP3 signaling (R-HSA-1489509)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Noncanonical activation of NOTCH3 (R-HSA-9017802)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Intracellular oxygen transport (R-HSA-8981607)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Anchoring fibril formation (R-HSA-2214320)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Recruitment of NuMA to mitotic centrosomes (R-HSA-380320)	93	0	.49	-	 < 0.01	1.00E00	1.00E00
Free fatty acid receptors (R-HSA-444209)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
MAPK targets/ Nuclear events mediated by MAP kinases (R-HSA-450282)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
p75NTR regulates axonogenesis (R-HSA-193697)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Golgi-to-ER retrograde transport (R-HSA-8856688)	134	0	.70	-	 < 0.01	1.00E00	1.00E00
MyD88 deficiency (TLR5) (R-HSA-5602680)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
GRB7 events in ERBB2 signaling (R-HSA-1306955)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Transport of Mature mRNA derived from an Intron-Containing Transcript (R-HSA-159236)	70	0	.37	-	 < 0.01	1.00E00	1.00E00
Reduction of cytosolic Ca++ levels (R-HSA-418359)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Regulated proteolysis of p75NTR (R-HSA-193692)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Transport of Mature mRNAs Derived from Intronless Transcripts (R-HSA-159234)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Transport of Mature mRNA Derived from an Intronless Transcript (R-HSA-159231)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Transport of the SLBP Dependant Mature mRNA (R-HSA-159230)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Diseases of Immune System (R-HSA-5260271)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Severe congenital neutropenia type 4 (G6PC3) (R-HSA-3282872)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Depolymerisation of the Nuclear Lamina (R-HSA-4419969)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Antiviral mechanism by IFN-stimulated genes (R-HSA-1169410)	70	0	.37	-	 < 0.01	1.00E00	1.00E00
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) (R-HSA-5619114)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
mRNA Editing (R-HSA-75072)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective SLC3A1 causes cystinuria (CSNU) (R-HSA-5619113)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) (R-HSA-5619111)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) (R-HSA-5619110)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Serotonin and melatonin biosynthesis (R-HSA-209931)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
HSF1 activation (R-HSA-3371511)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Zinc influx into cells by the SLC39 gene family (R-HSA-442380)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
The activation of arylsulfatases (R-HSA-1663150)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Transport of the SLBP independent Mature mRNA (R-HSA-159227)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Advanced glycosylation endproduct receptor signaling (R-HSA-879415)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Activated NTRK2 signals through CDK5 (R-HSA-9032845)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Ceramide signalling (R-HSA-193681)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Cell junction organization (R-HSA-446728)	91	0	.48	-	 < 0.01	1.00E00	1.00E00
Platelet homeostasis (R-HSA-418346)	88	0	.46	-	 < 0.01	1.00E00	1.00E00
Transport of fatty acids (R-HSA-804914)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
ISG15 antiviral mechanism (R-HSA-1169408)	70	0	.37	-	 < 0.01	1.00E00	1.00E00
Activation of GABAB receptors (R-HSA-991365)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Olfactory Signaling Pathway (R-HSA-381753)	432	0	2.26	-	 < 0.01	1.78E-01	1.00E00
Defective SLC6A2 causes orthostatic intolerance (OI) (R-HSA-5619109)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Processing of Capped Intronless Pre-mRNA (R-HSA-75067)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS) (R-HSA-5619108)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
mRNA Editing: A to I Conversion (R-HSA-75064)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Autointegration results in viral DNA circles (R-HSA-177539)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Negative regulation of TCF-dependent signaling by DVL-interacting proteins (R-HSA-5368598)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective SLC12A1 causes Bartter syndrome 1 (BS1) (R-HSA-5619104)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective DPM1 causes DPM1-CDG (CDG-1e) (R-HSA-4717374)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Collagen degradation (R-HSA-1442490)	64	0	.34	-	 < 0.01	1.00E00	1.00E00
Acetylcholine regulates insulin secretion (R-HSA-399997)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) (R-HSA-5619101)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
PAOs oxidise polyamines to amines (R-HSA-141334)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Transfer of LPS from LBP carrier to CD14 (R-HSA-166020)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB (R-HSA-141333)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Processing of Intronless Pre-mRNAs (R-HSA-77595)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Reactions specific to the complex N-glycan synthesis pathway (R-HSA-975578)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
N-Glycan antennae elongation (R-HSA-975577)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Free fatty acids regulate insulin secretion (R-HSA-400451)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
N-glycan antennae elongation in the medial/trans-Golgi (R-HSA-975576)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Reactions specific to the hybrid N-glycan synthesis pathway (R-HSA-975574)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
p75NTR negatively regulates cell cycle via SC1 (R-HSA-193670)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM) (R-HSA-5687583)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
The citric acid (TCA) cycle and respiratory electron transport (R-HSA-1428517)	173	0	.91	-	 < 0.01	1.00E00	1.00E00
Vasopressin-like receptors (R-HSA-388479)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Interleukin-12 signaling (R-HSA-9020591)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
TAK1 activates NFkB by phosphorylation and activation of IKKs complex (R-HSA-445989)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor 4 (TLR4) Cascade (R-HSA-166016)	127	0	.67	-	 < 0.01	1.00E00	1.00E00
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs (R-HSA-77588)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
ROS, RNS production in phagocytes (R-HSA-1222556)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
MET activates PTPN11 (R-HSA-8865999)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
O2/CO2 exchange in erythrocytes (R-HSA-1480926)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Opsins (R-HSA-419771)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Catecholamine biosynthesis (R-HSA-209905)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
RNA polymerase II transcribes snRNA genes (R-HSA-6807505)	74	0	.39	-	 < 0.01	1.00E00	1.00E00
Lysosphingolipid and LPA receptors (R-HSA-419408)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Toll-Like Receptors Cascades (R-HSA-168898)	152	0	.80	-	 < 0.01	1.00E00	1.00E00
Antimicrobial peptides (R-HSA-6803157)	90	0	.47	-	 < 0.01	1.00E00	1.00E00
Sodium-coupled phosphate cotransporters (R-HSA-427652)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Lysosomal oligosaccharide catabolism (R-HSA-8853383)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
NADPH regeneration (R-HSA-389542)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Activation of kainate receptors upon glutamate binding (R-HSA-451326)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
G-protein beta:gamma signalling (R-HSA-397795)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex (R-HSA-75035)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
RORA activates gene expression (R-HSA-1368082)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Lactose synthesis (R-HSA-5653890)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
ATF4 activates genes (R-HSA-380994)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Retrograde neurotrophin signalling (R-HSA-177504)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
IKBKB deficiency causes SCID (R-HSA-5602636)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
The IPAF inflammasome (R-HSA-844623)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
DAP12 signaling (R-HSA-2424491)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
NRAGE signals death through JNK (R-HSA-193648)	59	0	.31	-	 < 0.01	1.00E00	1.00E00
Defective Mismatch Repair Associated With MLH1 (R-HSA-5545483)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Phosphorylation of Emi1 (R-HSA-176417)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Phosphorylation of the APC/C (R-HSA-176412)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Hyaluronan biosynthesis and export (R-HSA-2142850)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Synthesis of diphthamide-EEF2 (R-HSA-5358493)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Interleukin-33 signaling (R-HSA-9014843)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Downregulation of ERBB2 signaling (R-HSA-8863795)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
NR1D1 (REV-ERBA) represses gene expression (R-HSA-1368071)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
CRMPs in Sema3A signaling (R-HSA-399956)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion (R-HSA-399955)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Sema3A PAK dependent Axon repulsion (R-HSA-399954)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
The AIM2 inflammasome (R-HSA-844615)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
BDNF activates NTRK2 (TRKB) signaling (R-HSA-9024909)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
p75NTR signals via NF-kB (R-HSA-193639)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) (R-HSA-5660686)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
RUNX2 regulates chondrocyte maturation (R-HSA-8941284)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase (R-HSA-176407)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
FGFR2b ligand binding and activation (R-HSA-190377)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Axonal growth inhibition (RHOA activation) (R-HSA-193634)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
FGFR2c ligand binding and activation (R-HSA-190375)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Hyaluronan metabolism (R-HSA-2142845)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
G alpha (12/13) signalling events (R-HSA-416482)	87	0	.46	-	 < 0.01	1.00E00	1.00E00
FGFR1c and Klotho ligand binding and activation (R-HSA-190374)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
FGFR1c ligand binding and activation (R-HSA-190373)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Mineralocorticoid biosynthesis (R-HSA-193993)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
FGFR3c ligand binding and activation (R-HSA-190372)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
FGFR3b ligand binding and activation (R-HSA-190371)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
FGFR1b ligand binding and activation (R-HSA-190370)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Beta-oxidation of pristanoyl-CoA (R-HSA-389887)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Signaling by NODAL (R-HSA-1181150)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Interleukin-2 signaling (R-HSA-9020558)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Activation of Ca-permeable Kainate Receptor (R-HSA-451308)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Activation of Na-permeable kainate receptors (R-HSA-451307)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Essential pentosuria (R-HSA-5662853)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Reversible hydration of carbon dioxide (R-HSA-1475029)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Ionotropic activity of kainate receptors (R-HSA-451306)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Downregulation of ERBB4 signaling (R-HSA-1253288)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Breakdown of the nuclear lamina (R-HSA-352238)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Serotonin clearance from the synaptic cleft (R-HSA-380615)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Metabolism of serotonin (R-HSA-380612)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Amino acid transport across the plasma membrane (R-HSA-352230)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Energy dependent regulation of mTOR by LKB1-AMPK (R-HSA-380972)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Agmatine biosynthesis (R-HSA-351143)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Major pathway of rRNA processing in the nucleolus and cytosol (R-HSA-6791226)	181	0	.95	-	 < 0.01	1.00E00	1.00E00
Collagen formation (R-HSA-1474290)	89	0	.47	-	 < 0.01	1.00E00	1.00E00
Highly calcium permeable nicotinic acetylcholine receptors (R-HSA-629597)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors (R-HSA-629594)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
PIWI-interacting RNA (piRNA) biogenesis (R-HSA-5601884)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Notch-HLH transcription pathway (R-HSA-350054)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
ERBB2 Activates PTK6 Signaling (R-HSA-8847993)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Intraflagellar transport (R-HSA-5620924)	53	0	.28	-	 < 0.01	1.00E00	1.00E00
Interleukin-36 pathway (R-HSA-9014826)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Signaling by Nuclear Receptors (R-HSA-9006931)	167	0	.87	-	 < 0.01	1.00E00	1.00E00
BBSome-mediated cargo-targeting to cilium (R-HSA-5620922)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Cargo trafficking to the periciliary membrane (R-HSA-5620920)	51	0	.27	-	 < 0.01	1.00E00	1.00E00
TRAF6-mediated induction of TAK1 complex within TLR4 complex (R-HSA-937072)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Mitochondrial iron-sulfur cluster biogenesis (R-HSA-1362409)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
GAB1 signalosome (R-HSA-180292)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
RNF mutants show enhanced WNT signaling and proliferation (R-HSA-5340588)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Activation of C3 and C5 (R-HSA-174577)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
CLEC7A/inflammasome pathway (R-HSA-5660668)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective GALNT12 causes colorectal cancer 1 (CRCS1) (R-HSA-5083636)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective B3GALTL causes Peters-plus syndrome (PpS) (R-HSA-5083635)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
NOTCH2 Activation and Transmission of Signal to the Nucleus (R-HSA-2979096)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 (R-HSA-5083633)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Proton/oligopeptide cotransporters (R-HSA-427975)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Highly sodium permeable acetylcholine nicotinic receptors (R-HSA-629587)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) (R-HSA-5083632)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective LFNG causes SCDO3 (R-HSA-5083630)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
MyD88 cascade initiated on plasma membrane (R-HSA-975871)	84	0	.44	-	 < 0.01	1.00E00	1.00E00
PKB-mediated events (R-HSA-109703)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
MAP3K8 (TPL2)-dependent MAPK1/3 activation (R-HSA-5684264)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
p130Cas linkage to MAPK signaling for integrins (R-HSA-372708)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
VxPx cargo-targeting to cilium (R-HSA-5620916)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of DPAn-3 SPMs (R-HSA-9025094)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of Cell Death Genes (R-HSA-5633008)	43	0	.23	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Activity (R-HSA-5633007)	159	0	.83	-	 < 0.01	1.00E00	1.00E00
Adherens junctions interactions (R-HSA-418990)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Defective ABCC8 can cause hypoglycemias and hyperglycemias (R-HSA-5683177)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants (R-HSA-2894862)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
Anchoring of the basal body to the plasma membrane (R-HSA-5620912)	96	0	.50	-	 < 0.01	1.00E00	1.00E00
Dopamine Neurotransmitter Release Cycle (R-HSA-212676)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
TRIF(TICAM1)-mediated TLR4 signaling  (R-HSA-937061)	97	0	.51	-	 < 0.01	1.00E00	1.00E00
Signaling by ERBB4 (R-HSA-1236394)	41	0	.21	-	 < 0.01	1.00E00	1.00E00
Defective CD320 causes methylmalonic aciduria (R-HSA-3359485)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Activation of DNA fragmentation factor (R-HSA-211227)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Na+/Cl- dependent neurotransmitter transporters (R-HSA-442660)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 (R-HSA-5083629)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974 (R-HSA-5340573)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 (R-HSA-5083628)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Nuclear Pore Complex (NPC) Disassembly (R-HSA-3301854)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Defective LARGE causes MDDGA6 and MDDGB6 (R-HSA-5083627)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
DSCAM interactions (R-HSA-376172)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) (R-HSA-5083625)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) (R-HSA-2142816)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Signaling by FGFR3 point mutants in cancer (R-HSA-8853338)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
via Death Receptors in the presence of ligand (R-HSA-140534)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Signaling by plasma membrane FGFR1 fusions (R-HSA-8853336)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Multifunctional anion exchangers (R-HSA-427601)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Signaling by FGFR3 fusions in cancer (R-HSA-8853334)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
TGFBR2 MSI Frameshift Mutants in Cancer (R-HSA-3642279)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Loss of Function of TGFBR2 in Cancer (R-HSA-3642278)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer (R-HSA-2894858)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
Methionine salvage pathway (R-HSA-1237112)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
RUNX3 regulates YAP1-mediated transcription (R-HSA-8951671)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Inositol phosphate metabolism (R-HSA-1483249)	48	0	.25	-	 < 0.01	1.00E00	1.00E00
Synthesis of PIPs at the ER membrane (R-HSA-1483248)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
mRNA Capping (R-HSA-72086)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Terminal pathway of complement (R-HSA-166665)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
PRC2 methylates histones and DNA (R-HSA-212300)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Defective MUT causes methylmalonic aciduria mut type (R-HSA-3359478)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Initial triggering of complement (R-HSA-166663)	85	0	.45	-	 < 0.01	1.00E00	1.00E00
Lectin pathway of complement activation (R-HSA-166662)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Purine catabolism (R-HSA-74259)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants (R-HSA-1236382)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Defective MMAA causes methylmalonic aciduria type cblA (R-HSA-3359475)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC (R-HSA-3359474)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD (R-HSA-3359473)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective MMAB causes methylmalonic aciduria type cblB (R-HSA-3359471)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Acetylcholine Neurotransmitter Release Cycle (R-HSA-264642)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Binding and entry of HIV virion (R-HSA-173107)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Trafficking and processing of endosomal TLR (R-HSA-1679131)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
DAP12 interactions (R-HSA-2172127)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF) (R-HSA-5687868)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Relaxin receptors (R-HSA-444821)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Gamma-carboxylation, transport, and amino-terminal cleavage of proteins (R-HSA-159854)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Chylomicron remodeling (R-HSA-8963901)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Activated NTRK2 signals through PI3K (R-HSA-9028335)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Clearance of Nuclear Envelope Membranes from Chromatin (R-HSA-2993913)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Gap-filling DNA repair synthesis and ligation in TC-NER (R-HSA-6782210)	64	0	.34	-	 < 0.01	1.00E00	1.00E00
Glutathione conjugation (R-HSA-156590)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
HHAT G278V abrogates palmitoylation of Hh-Np (R-HSA-5658034)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
The canonical retinoid cycle in rods (twilight vision) (R-HSA-2453902)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2 (R-HSA-5678520)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
TRP channels (R-HSA-3295583)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Complement cascade (R-HSA-166658)	120	0	.63	-	 < 0.01	1.00E00	1.00E00
Mitotic Spindle Checkpoint (R-HSA-69618)	108	0	.57	-	 < 0.01	1.00E00	1.00E00
IRAK2 mediated activation of TAK1 complex (R-HSA-937042)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
IKK complex recruitment mediated by RIP1 (R-HSA-937041)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Defective CHSY1 causes TPBS (R-HSA-3595177)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
RAB GEFs exchange GTP for GDP on RABs (R-HSA-8876198)	89	0	.47	-	 < 0.01	1.00E00	1.00E00
Defective MTR causes methylmalonic aciduria and homocystinuria type cblG (R-HSA-3359469)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE (R-HSA-3359467)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CHST14 causes EDS, musculocontractural type (R-HSA-3595174)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Synthesis and processing of ENV and VPU (R-HSA-171286)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CHST3 causes SEDCJD (R-HSA-3595172)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Invadopodia formation (R-HSA-8941237)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective CUBN causes hereditary megaloblastic anemia 1 (R-HSA-3359463)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Homologous DNA Pairing and Strand Exchange (R-HSA-5693579)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Defective AMN causes hereditary megaloblastic anemia 1 (R-HSA-3359462)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Activation of E2F1 target genes at G1/S (R-HSA-539107)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
TWIK related potassium channel (TREK) (R-HSA-1299503)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
NOTCH4 Activation and Transmission of Signal to the Nucleus (R-HSA-9013700)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Formation of Fibrin Clot (Clotting Cascade) (R-HSA-140877)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits (R-HSA-997272)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Common Pathway of Fibrin Clot Formation (R-HSA-140875)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Glucuronidation (R-HSA-156588)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Mitotic Telophase/Cytokinesis (R-HSA-68884)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Nonhomologous End-Joining (NHEJ) (R-HSA-5693571)	52	0	.27	-	 < 0.01	1.00E00	1.00E00
Amino Acid conjugation (R-HSA-156587)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Mitotic Metaphase/Anaphase Transition (R-HSA-68881)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
G0 and Early G1 (R-HSA-1538133)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Cytosolic sulfonation of small molecules (R-HSA-156584)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Acetylation (R-HSA-156582)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Methylation (R-HSA-156581)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Phase II - Conjugation of compounds (R-HSA-156580)	108	0	.57	-	 < 0.01	1.00E00	1.00E00
IRAK1 recruits IKK complex (R-HSA-937039)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Synthesis of PI (R-HSA-1483226)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF (R-HSA-3359458)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
SUMOylation of RNA binding proteins (R-HSA-4570464)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Defective GIF causes intrinsic factor deficiency (R-HSA-3359457)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
mRNA decay by 5' to 3' exoribonuclease (R-HSA-430039)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Vitamin B5 (pantothenate) metabolism (R-HSA-199220)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Defective TCN2 causes hereditary megaloblastic anemia (R-HSA-3359454)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Inhibition of adenylate cyclase pathway (R-HSA-997269)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Dopamine clearance from the synaptic cleft (R-HSA-379401)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Resolution of D-loop Structures through Holliday Junction Intermediates (R-HSA-5693568)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) (R-HSA-5693567)	114	0	.60	-	 < 0.01	1.00E00	1.00E00
HuR (ELAVL1) binds and stabilizes mRNA (R-HSA-450520)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
ALKBH3 mediated reversal of alkylation damage (R-HSA-112126)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks (R-HSA-5693565)	59	0	.31	-	 < 0.01	1.00E00	1.00E00
Mitotic Prometaphase (R-HSA-68877)	194	0	1.02	-	 < 0.01	6.30E-01	1.00E00
Mitotic Prophase (R-HSA-68875)	103	0	.54	-	 < 0.01	1.00E00	1.00E00
ALKBH2 mediated reversal of alkylation damage (R-HSA-112122)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of PE (R-HSA-1483213)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Regulation of IFNA signaling (R-HSA-912694)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Ras activation upon Ca2+ influx through NMDA receptor (R-HSA-442982)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA (R-HSA-450513)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
GLI proteins bind promoters of Hh responsive genes to promote transcription (R-HSA-5635851)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) (R-HSA-5693554)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
RET signaling (R-HSA-8853659)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Glycogen storage disease type 0 (muscle GYS1) (R-HSA-3828062)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
NTF3 activates NTRK2 (TRKB) signaling (R-HSA-9025046)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Molecules associated with elastic fibres (R-HSA-2129379)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Inactivation, recovery and regulation of the phototransduction cascade (R-HSA-2514859)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Degradation of the extracellular matrix (R-HSA-1474228)	140	0	.73	-	 < 0.01	1.00E00	1.00E00
Purine salvage (R-HSA-74217)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
The phototransduction cascade (R-HSA-2514856)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Sensing of DNA Double Strand Breaks (R-HSA-5693548)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
NOSTRIN mediated eNOS trafficking (R-HSA-203641)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Cytochrome P450 - arranged by substrate type (R-HSA-211897)	65	0	.34	-	 < 0.01	1.00E00	1.00E00
Condensation of Prometaphase Chromosomes (R-HSA-2514853)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Glycine degradation (R-HSA-6783984)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Cytosolic sensors of pathogen-associated DNA  (R-HSA-1834949)	63	0	.33	-	 < 0.01	1.00E00	1.00E00
Signaling by NTRK3 (TRKC) (R-HSA-9034015)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
NTF3 activates NTRK3 signaling (R-HSA-9034013)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Sperm:Oocyte Membrane Binding (R-HSA-1300652)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
STING mediated induction of host immune responses (R-HSA-1834941)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha (R-HSA-1234162)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Glucagon signaling in metabolic regulation (R-HSA-163359)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
PKA-mediated phosphorylation of key metabolic factors (R-HSA-163358)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Beta-catenin phosphorylation cascade (R-HSA-196299)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Negative feedback regulation of MAPK pathway (R-HSA-5674499)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Activation of SMO (R-HSA-5635838)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Homology Directed Repair (R-HSA-5693538)	120	0	.63	-	 < 0.01	1.00E00	1.00E00
Resolution of D-Loop Structures (R-HSA-5693537)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Intrinsic Pathway of Fibrin Clot Formation (R-HSA-140837)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Regulated Necrosis (R-HSA-5218859)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
DNA Double-Strand Break Repair (R-HSA-5693532)	148	0	.78	-	 < 0.01	1.00E00	1.00E00
Extrinsic Pathway of Fibrin Clot Formation (R-HSA-140834)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Acrosome Reaction (R-HSA-1300645)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Interaction With The Zona Pellucida (R-HSA-1300644)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Regulation of gene expression by Hypoxia-inducible Factor (R-HSA-1234158)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Sperm Motility And Taxes (R-HSA-1300642)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Signaling by activated point mutants of FGFR3 (R-HSA-1839130)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Regulation of PTEN mRNA translation (R-HSA-8943723)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
T41 mutants of beta-catenin aren't phosphorylated (R-HSA-5358752)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Heme degradation (R-HSA-189483)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
S45 mutants of beta-catenin aren't phosphorylated (R-HSA-5358751)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
SLBP independent Processing of Histone Pre-mRNAs (R-HSA-111367)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Pre-NOTCH Expression and Processing (R-HSA-1912422)	78	0	.41	-	 < 0.01	1.00E00	1.00E00
Signaling by BMP (R-HSA-201451)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Pre-NOTCH Processing in Golgi (R-HSA-1912420)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Signal regulatory protein family interactions (R-HSA-391160)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Mitochondrial tRNA aminoacylation (R-HSA-379726)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
tRNA Aminoacylation (R-HSA-379724)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Termination of translesion DNA synthesis (R-HSA-5656169)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
S37 mutants of beta-catenin aren't phosphorylated (R-HSA-5358749)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Defective GALT can cause Galactosemia (R-HSA-5609978)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
S33 mutants of beta-catenin aren't phosphorylated (R-HSA-5358747)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
FGFR1 mutant receptor activation (R-HSA-1839124)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Defective GALE can cause Epimerase-deficiency galactosemia (EDG) (R-HSA-5609977)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes (R-HSA-170145)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective GALK1 can cause Galactosemia II (GALCT2) (R-HSA-5609976)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Signaling by activated point mutants of FGFR1 (R-HSA-1839122)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Diseases associated with glycosylation precursor biosynthesis (R-HSA-5609975)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Defective PGM1 causes PGM1-CDG (CDG1t) (R-HSA-5609974)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
HDL remodeling (R-HSA-8964058)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Interleukin-2 family signaling (R-HSA-451927)	44	0	.23	-	 < 0.01	1.00E00	1.00E00
Regulation of cholesterol biosynthesis by SREBP (SREBF) (R-HSA-1655829)	53	0	.28	-	 < 0.01	1.00E00	1.00E00
eNOS activation (R-HSA-203615)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Cytosolic tRNA aminoacylation (R-HSA-379716)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
InlA-mediated entry of Listeria monocytogenes into host cells (R-HSA-8876493)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Creatine metabolism (R-HSA-71288)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Signaling by cytosolic FGFR1 fusion mutants (R-HSA-1839117)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Pre-NOTCH Transcription and Translation (R-HSA-1912408)	62	0	.32	-	 < 0.01	1.00E00	1.00E00
Defective MOGS causes MOGS-CDG (CDG-2b) (R-HSA-4793954)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
GPVI-mediated activation cascade (R-HSA-114604)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) (R-HSA-4793953)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of wybutosine at G37 of tRNA(Phe) (R-HSA-6782861)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective MGAT2 causes MGAT2-CDG (CDG-2a) (R-HSA-4793952)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
VLDL clearance (R-HSA-8964046)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective MAN1B1 causes MRT15 (R-HSA-4793950)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Plasma lipoprotein clearance (R-HSA-8964043)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
LDL remodeling (R-HSA-8964041)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
RHO GTPases activate PKNs (R-HSA-5625740)	63	0	.33	-	 < 0.01	1.00E00	1.00E00
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation (R-HSA-8950505)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Biological oxidations (R-HSA-211859)	220	0	1.15	-	 < 0.01	6.33E-01	1.00E00
E2F mediated regulation of DNA replication (R-HSA-113510)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
AMPK inhibits chREBP transcriptional activation activity (R-HSA-163680)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Late Phase of HIV Life Cycle (R-HSA-162599)	135	0	.71	-	 < 0.01	1.00E00	1.00E00
Acyl chain remodeling of CL (R-HSA-1482798)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Early Phase of HIV Life Cycle (R-HSA-162594)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Integration of provirus (R-HSA-162592)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Glycogen storage disease type XV (GYG1) (R-HSA-3814836)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Heme biosynthesis (R-HSA-189451)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
LDL clearance (R-HSA-8964038)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Expression and Processing of Neurotrophins (R-HSA-9036866)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Mitochondrial transcription termination (R-HSA-163316)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
E2F-enabled inhibition of pre-replication complex formation (R-HSA-113507)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Regulation of signaling by CBL (R-HSA-912631)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Inhibition of replication initiation of damaged DNA by RB1/E2F1 (R-HSA-113501)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Plasma lipoprotein assembly, remodeling, and clearance (R-HSA-174824)	67	0	.35	-	 < 0.01	1.00E00	1.00E00
Interleukin-15 signaling (R-HSA-8983432)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Reverse Transcription of HIV RNA (R-HSA-162589)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Formation of the cornified envelope (R-HSA-6809371)	129	0	.68	-	 < 0.01	1.00E00	1.00E00
Vitamins B6 activation to pyridoxal phosphate (R-HSA-964975)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Termination of O-glycan biosynthesis (R-HSA-977068)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Budding and maturation of HIV virion (R-HSA-162588)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Acyl chain remodelling of PC (R-HSA-1482788)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
HIV Life Cycle (R-HSA-162587)	148	0	.78	-	 < 0.01	1.00E00	1.00E00
Carnitine synthesis (R-HSA-71262)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Uncoating of the HIV Virion (R-HSA-162585)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Alternative complement activation (R-HSA-173736)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Activated NOTCH1 Transmits Signal to the Nucleus (R-HSA-2122948)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
SOS-mediated signalling (R-HSA-112412)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
MAPK1 (ERK2) activation (R-HSA-112411)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
PI3K events in ERBB2 signaling (R-HSA-1963642)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
RAF activation (R-HSA-5673000)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Metabolism of porphyrins (R-HSA-189445)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
GRB2 events in ERBB2 signaling (R-HSA-1963640)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
RUNX3 regulates p14-ARF (R-HSA-8951936)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Cilium Assembly (R-HSA-5617833)	200	0	1.05	-	 < 0.01	6.30E-01	1.00E00
Threonine catabolism (R-HSA-8849175)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Chylomicron clearance (R-HSA-8964026)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Synthesis of IPs in the ER lumen (R-HSA-1855231)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization (R-HSA-180897)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Interleukin-12 family signaling (R-HSA-447115)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD) (R-HSA-5578999)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD) (R-HSA-5578998)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD) (R-HSA-5578997)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX) (R-HSA-5578996)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of E-series 18(S)-resolvins (R-HSA-9018896)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency) (R-HSA-5578995)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components (R-HSA-446388)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
O-linked glycosylation of mucins (R-HSA-913709)	65	0	.34	-	 < 0.01	1.00E00	1.00E00
Metal sequestration by antimicrobial proteins (R-HSA-6799990)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Translesion synthesis by POLI (R-HSA-5656121)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Bile acid and bile salt metabolism (R-HSA-194068)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Transport of nucleotide sugars (R-HSA-727802)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates transcription of genes involved in WNT signaling (R-HSA-8939256)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Chain Elongation (R-HSA-73780)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II Transcription Elongation (R-HSA-75955)	61	0	.32	-	 < 0.01	1.00E00	1.00E00
HDL clearance (R-HSA-8964011)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Formation of the ternary complex, and subsequently, the 43S complex (R-HSA-72695)	51	0	.27	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II Transcription Initiation (R-HSA-75953)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
RUNX3 regulates NOTCH signaling (R-HSA-8941856)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Essential fructosuria (R-HSA-5657562)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
RUNX3 regulates CDKN1A transcription (R-HSA-8941855)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
HDR through Homologous Recombination (HRR) (R-HSA-5685942)	66	0	.35	-	 < 0.01	1.00E00	1.00E00
Hereditary fructose intolerance (R-HSA-5657560)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Interleukin-9 signaling (R-HSA-8985947)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Signalling to ERK5 (R-HSA-198765)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Tryptophan catabolism (R-HSA-71240)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
PERK regulates gene expression (R-HSA-381042)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Defective SLC6A19 causes Hartnup disorder (HND) (R-HSA-5659735)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening (R-HSA-73779)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase I Chain Elongation (R-HSA-73777)	59	0	.31	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II Promoter Escape (R-HSA-73776)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
InlB-mediated entry of Listeria monocytogenes into host cell (R-HSA-8875360)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Eukaryotic Translation Elongation (R-HSA-156842)	94	0	.49	-	 < 0.01	1.00E00	1.00E00
IRAK4 deficiency (TLR2/4) (R-HSA-5603041)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates transcription of genes involved in interleukin signaling (R-HSA-8939247)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase I Promoter Escape (R-HSA-73772)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Glycogen storage disease type II (GAA) (R-HSA-5357609)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells (R-HSA-8939246)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates transcription of genes involved in BCR signaling (R-HSA-8939245)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Nectin/Necl  trans heterodimerization (R-HSA-420597)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Formation of a pool of free 40S subunits (R-HSA-72689)	101	0	.53	-	 < 0.01	1.00E00	1.00E00
RUNX3 regulates RUNX1-mediated transcription (R-HSA-8951911)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes (R-HSA-8939242)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
RA biosynthesis pathway (R-HSA-5365859)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Transcription from mitochondrial promoters (R-HSA-75944)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
ECM proteoglycans (R-HSA-3000178)	76	0	.40	-	 < 0.01	1.00E00	1.00E00
MicroRNA (miRNA) biogenesis (R-HSA-203927)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Estrogen-dependent gene expression (R-HSA-9018519)	118	0	.62	-	 < 0.01	1.00E00	1.00E00
HDR through MMEJ (alt-NHEJ) (R-HSA-5685939)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
HDR through Single Strand Annealing (SSA) (R-HSA-5685938)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
Non-integrin membrane-ECM interactions (R-HSA-3000171)	59	0	.31	-	 < 0.01	1.00E00	1.00E00
Fertilization (R-HSA-1187000)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Syndecan interactions (R-HSA-3000170)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
IL-6-type cytokine receptor ligand interactions (R-HSA-6788467)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Processing of SMDT1 (R-HSA-8949664)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria (R-HSA-5659729)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of protectin and resolvin conjugates in tissue regeneration (PCTR and RCTR) (R-HSA-9026766)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of DPAn-3-derived 13-series resolvins (R-HSA-9026403)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
ATF6 (ATF6-alpha) activates chaperones (R-HSA-381033)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
ERK/MAPK targets (R-HSA-198753)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
IRAK4 deficiency (TLR5) (R-HSA-5603037)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Collagen chain trimerization (R-HSA-8948216)	44	0	.23	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of maresin conjugates in tissue regeneration (MCTR) (R-HSA-9026762)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Reelin signalling pathway (R-HSA-8866376)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling (R-HSA-2644607)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Constitutive Signaling by NOTCH1 PEST Domain Mutants (R-HSA-2644606)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase I Transcription Initiation (R-HSA-73762)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
Signaling by Activin (R-HSA-1502540)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
FBXW7 Mutants and NOTCH1 in Cancer (R-HSA-2644605)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Synthesis of IP3 and IP4 in the cytosol (R-HSA-1855204)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Signaling by NOTCH1 in Cancer (R-HSA-2644603)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
Signaling by NOTCH1 PEST Domain Mutants in Cancer (R-HSA-2644602)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
Axonal growth stimulation (R-HSA-209563)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
TNFR1-induced NFkappaB signaling pathway (R-HSA-5357956)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
NF-kB is activated and signals survival (R-HSA-209560)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Endosomal/Vacuolar pathway (R-HSA-1236977)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
rRNA processing (R-HSA-72312)	201	0	1.05	-	 < 0.01	6.30E-01	1.00E00
Cross-presentation of particulate exogenous antigens (phagosomes) (R-HSA-1236973)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Role of phospholipids in phagocytosis (R-HSA-2029485)	88	0	.46	-	 < 0.01	1.00E00	1.00E00
Signalling to STAT3 (R-HSA-198745)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Cell-extracellular matrix interactions (R-HSA-446353)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
IkBA variant leads to EDA-ID (R-HSA-5603029)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Regulation of actin dynamics for phagocytic cup formation (R-HSA-2029482)	123	0	.64	-	 < 0.01	1.00E00	1.00E00
L13a-mediated translational silencing of Ceruloplasmin expression (R-HSA-156827)	111	0	.58	-	 < 0.01	1.00E00	1.00E00
FCGR activation (R-HSA-2029481)	74	0	.39	-	 < 0.01	1.00E00	1.00E00
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) (R-HSA-5603027)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Fcgamma receptor (FCGR) dependent phagocytosis (R-HSA-2029480)	147	0	.77	-	 < 0.01	1.00E00	1.00E00
Defective AVP causes neurohypophyseal diabetes insipidus (NDI) (R-HSA-5619099)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
rRNA modification in the mitochondrion (R-HSA-6793080)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS) (R-HSA-5619098)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) (R-HSA-5619097)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
TRAF3-dependent IRF activation pathway (R-HSA-918233)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1) (R-HSA-5619096)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2) (R-HSA-5619095)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Variant SLC6A14 may confer susceptibility towards obesity (R-HSA-5619094)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
HSP90 chaperone cycle for steroid hormone receptors (SHR) (R-HSA-3371497)	56	0	.29	-	 < 0.01	1.00E00	1.00E00
Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH) (R-HSA-5619092)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Visual phototransduction (R-HSA-2187338)	97	0	.51	-	 < 0.01	1.00E00	1.00E00
FGFRL1 modulation of FGFR1 signaling (R-HSA-5658623)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Conjugation of phenylacetate with glutamine (R-HSA-177162)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
RAS signaling downstream of NF1 loss-of-function variants (R-HSA-6802953)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
The retinoid cycle in cones (daylight vision) (R-HSA-2187335)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor TLR6:TLR2 Cascade (R-HSA-168188)	94	0	.49	-	 < 0.01	1.00E00	1.00E00
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S (R-HSA-72662)	59	0	.31	-	 < 0.01	1.00E00	1.00E00
ARL13B-mediated ciliary trafficking of INPP5E (R-HSA-5624958)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
PTEN Loss of Function in Cancer (R-HSA-5674404)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor 7/8 (TLR7/8) Cascade (R-HSA-168181)	92	0	.48	-	 < 0.01	1.00E00	1.00E00
Signaling by ERBB2 (R-HSA-1227986)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
Constitutive Signaling by AKT1 E17K in Cancer (R-HSA-5674400)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Prolactin receptor signaling (R-HSA-1170546)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Localization of the PINCH-ILK-PARVIN complex to focal adhesions (R-HSA-446343)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Protein repair (R-HSA-5676934)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Regulation by TREX1 (R-HSA-3248023)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC6A5 causes hyperekplexia 3 (HKPX3) (R-HSA-5619089)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
WNT5A-dependent internalization of FZD4 (R-HSA-5099900)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ) (R-HSA-5619088)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC12A3 causes Gitelman syndrome (GS) (R-HSA-5619087)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Centrosome maturation (R-HSA-380287)	80	0	.42	-	 < 0.01	1.00E00	1.00E00
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1) (R-HSA-5619085)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
CaM pathway (R-HSA-111997)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Ca-dependent events (R-HSA-111996)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS) (R-HSA-5619083)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Loss of proteins required for interphase microtubule organization from the centrosome (R-HSA-380284)	68	0	.36	-	 < 0.01	1.00E00	1.00E00
phospho-PLA2 pathway (R-HSA-111995)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
p75NTR recruits signalling complexes (R-HSA-209543)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) (R-HSA-5619081)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
ESR-mediated signaling (R-HSA-8939211)	124	0	.65	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor TLR1:TLR2 Cascade (R-HSA-168179)	97	0	.51	-	 < 0.01	1.00E00	1.00E00
PKA activation (R-HSA-163615)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor 5 (TLR5) Cascade (R-HSA-168176)	84	0	.44	-	 < 0.01	1.00E00	1.00E00
Signal amplification (R-HSA-392518)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Nuclear Events (kinase and transcription factor activation) (R-HSA-198725)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Abacavir metabolism (R-HSA-2161541)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria (R-HSA-5619079)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C) (R-HSA-5619078)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D) (R-HSA-5619077)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25) (R-HSA-5619076)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Phenylketonuria (R-HSA-2160456)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
PTK6 Activates STAT3 (R-HSA-8849474)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
PTK6 Expression (R-HSA-8849473)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M) (R-HSA-5619072)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Translation initiation complex formation (R-HSA-72649)	58	0	.30	-	 < 0.01	1.00E00	1.00E00
PTK6 Down-Regulation (R-HSA-8849472)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1) (R-HSA-5619071)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases (R-HSA-8849471)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) (R-HSA-5619070)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
PTK6 Regulates Cell Cycle (R-HSA-8849470)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
NCAM1 interactions (R-HSA-419037)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Recruitment of mitotic centrosome proteins and complexes (R-HSA-380270)	80	0	.42	-	 < 0.01	1.00E00	1.00E00
Fructose metabolism (R-HSA-5652084)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Scavenging by Class H Receptors (R-HSA-3000497)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor 3 (TLR3) Cascade (R-HSA-168164)	96	0	.50	-	 < 0.01	1.00E00	1.00E00
Adrenoceptors (R-HSA-390696)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
SUMOylation of DNA replication proteins (R-HSA-4615885)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase I Promoter Opening (R-HSA-73728)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Defective SLC2A10 causes arterial tortuosity syndrome (ATS) (R-HSA-5619068)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
PTK6 Regulates Proteins Involved in RNA Processing (R-HSA-8849468)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) (R-HSA-5619067)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1) (R-HSA-5619066)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
SUMOylation of chromatin organization proteins (R-HSA-4551638)	52	0	.27	-	 < 0.01	1.00E00	1.00E00
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS) (R-HSA-5619063)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC1A3 causes episodic ataxia 6 (EA6) (R-HSA-5619062)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Nuclear Envelope Reassembly (R-HSA-2995410)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Conjugation of benzoate with glycine (R-HSA-177135)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Glucocorticoid biosynthesis (R-HSA-194002)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective SLC33A1 causes spastic paraplegia 42 (SPG42) (R-HSA-5619061)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Interaction With Cumulus Cells (R-HSA-2534343)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CP causes aceruloplasminemia (ACERULOP) (R-HSA-5619060)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Signaling by FGFR3 in disease (R-HSA-5655332)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Scavenging by Class F Receptors (R-HSA-3000484)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
RHO GTPases Activate Formins (R-HSA-5663220)	135	0	.71	-	 < 0.01	1.00E00	1.00E00
Carboxyterminal post-translational modifications of tubulin (R-HSA-8955332)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Scavenging by Class A Receptors (R-HSA-3000480)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Cristae formation (R-HSA-8949613)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Serine biosynthesis (R-HSA-977347)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Abacavir transport and metabolism (R-HSA-2161522)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective ALG1 causes ALG1-CDG (CDG-1k) (R-HSA-4549380)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
NGF processing (R-HSA-167060)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR) (R-HSA-5619058)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Activation of PUMA and translocation to mitochondria (R-HSA-139915)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Loss of Nlp from mitotic centrosomes (R-HSA-380259)	68	0	.36	-	 < 0.01	1.00E00	1.00E00
Prostacyclin signalling through prostacyclin receptor (R-HSA-392851)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective HK1 causes hexokinase deficiency (HK deficiency) (R-HSA-5619056)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Nuclear signaling by ERBB4 (R-HSA-1251985)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI) (R-HSA-5619055)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Conjugation of salicylate with glycine (R-HSA-177128)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) (R-HSA-5619054)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP) (R-HSA-5619053)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Activation of BMF and translocation to mitochondria (R-HSA-139910)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective SLC9A9 causes autism 16 (AUTS16) (R-HSA-5619052)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) (R-HSA-5619050)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Regulation of HSF1-mediated heat shock response (R-HSA-3371453)	67	0	.35	-	 < 0.01	1.00E00	1.00E00
CREB3 factors activate genes (R-HSA-8874211)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Regulation of TNFR1 signaling (R-HSA-5357905)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Adrenaline,noradrenaline inhibits insulin secretion (R-HSA-400042)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
RHO GTPases Activate WASPs and WAVEs (R-HSA-5663213)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor 10 (TLR10) Cascade (R-HSA-168142)	84	0	.44	-	 < 0.01	1.00E00	1.00E00
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation (R-HSA-975163)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Interactions of Tat with host cellular proteins (R-HSA-176034)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Scavenging by Class B Receptors (R-HSA-3000471)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Interactions of Vpr with host cellular proteins (R-HSA-176033)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Defective GFPT1 causes CMSTA1 (R-HSA-4085023)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Abacavir transmembrane transport (R-HSA-2161517)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
MET receptor recycling (R-HSA-8875656)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages) (R-HSA-5619049)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) (R-HSA-5619048)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2) (R-HSA-5619047)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC26A4 causes Pendred syndrome (PDS) (R-HSA-5619046)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM) (R-HSA-5619045)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Cam-PDE 1 activation (R-HSA-111957)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective SLC6A19 causes Hartnup disorder (HND) (R-HSA-5619044)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) (R-HSA-5619043)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN) (R-HSA-5619042)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG) (R-HSA-5619041)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1) (R-HSA-5619040)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor 9 (TLR9) Cascade (R-HSA-168138)	96	0	.50	-	 < 0.01	1.00E00	1.00E00
Organelle biogenesis and maintenance (R-HSA-1852241)	292	0	1.53	-	 < 0.01	4.11E-01	1.00E00
Eukaryotic Translation Initiation (R-HSA-72613)	119	0	.62	-	 < 0.01	1.00E00	1.00E00
TYSND1 cleaves peroxisomal proteins (R-HSA-9033500)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
MyD88 dependent cascade initiated on endosome (R-HSA-975155)	92	0	.48	-	 < 0.01	1.00E00	1.00E00
Phospholipase C-mediated cascade; FGFR3 (R-HSA-5654227)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
SUMOylation of SUMOylation proteins (R-HSA-4085377)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Serotonin receptors (R-HSA-390666)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2 (R-HSA-4085011)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Phospholipase C-mediated cascade; FGFR2 (R-HSA-5654221)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of DNA Repair Genes (R-HSA-6796648)	65	0	.34	-	 < 0.01	1.00E00	1.00E00
COX reactions (R-HSA-140180)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Signalling to RAS (R-HSA-167044)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) (R-HSA-5619039)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F) (R-HSA-5619037)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6) (R-HSA-5619036)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC17A5 causes Salla disease (SD) and ISSD (R-HSA-5619035)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Response of Mtb to phagocytosis (R-HSA-1222499)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Cyclin A/B1/B2 associated events during G2/M transition (R-HSA-69273)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Signaling by FGFR1 in disease (R-HSA-5655302)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Activation of Matrix Metalloproteinases (R-HSA-1592389)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Signaling by Retinoic Acid (R-HSA-5362517)	43	0	.23	-	 < 0.01	1.00E00	1.00E00
Phospholipase C-mediated cascade: FGFR1 (R-HSA-5654219)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Amine Oxidase reactions (R-HSA-140179)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Protein methylation (R-HSA-8876725)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation (R-HSA-975144)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Formyl peptide receptors bind formyl peptides and many other ligands (R-HSA-444473)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Expression and Degradation (R-HSA-6806003)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
Sialic acid metabolism (R-HSA-4085001)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2 (R-HSA-4549356)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Dopamine receptors (R-HSA-390651)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Histamine receptors (R-HSA-390650)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Glycogen storage disease type Ia (G6PC) (R-HSA-3274531)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion (R-HSA-381676)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Transcription Initiation From Type 3 Promoter (R-HSA-76071)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Signaling by PDGF (R-HSA-186797)	55	0	.29	-	 < 0.01	1.00E00	1.00E00
Glycogen storage disease type IV (GBE1) (R-HSA-3878781)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
E3 ubiquitin ligases ubiquitinate target proteins (R-HSA-8866654)	54	0	.28	-	 < 0.01	1.00E00	1.00E00
Synthesis of active ubiquitin: roles of E1 and E2 enzymes (R-HSA-8866652)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Calmodulin induced events (R-HSA-111933)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
CaMK IV-mediated phosphorylation of CREB (R-HSA-111932)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
PKA-mediated phosphorylation of CREB (R-HSA-111931)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation (R-HSA-975138)	91	0	.48	-	 < 0.01	1.00E00	1.00E00
Muscarinic acetylcholine receptors (R-HSA-390648)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
NTRK2 activates RAC1 (R-HSA-9032759)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective ALG2 causes ALG2-CDG (CDG-1i) (R-HSA-4549349)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Cleavage of Growing Transcript in the Termination Region  (R-HSA-109688)	66	0	.35	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Transcription Initiation From Type 2 Promoter (R-HSA-76066)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Transcription Initiation From Type 1 Promoter (R-HSA-76061)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
PLC-gamma1 signalling (R-HSA-167021)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
tRNA processing in the mitochondrion (R-HSA-6785470)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
VEGF ligand-receptor interactions (R-HSA-194313)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
DNA methylation (R-HSA-5334118)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
Type II Na+/Pi cotransporters (R-HSA-427589)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
TRAF3 deficiency - HSE (R-HSA-5602571)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Plasma lipoprotein remodeling (R-HSA-8963899)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Vitamin B2 (riboflavin) metabolism (R-HSA-196843)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Plasma lipoprotein assembly (R-HSA-8963898)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
HDL assembly (R-HSA-8963896)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Regulation of innate immune responses to cytosolic DNA (R-HSA-3134975)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production (R-HSA-3134973)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
GDP-fucose biosynthesis (R-HSA-6787639)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Post-transcriptional silencing by small RNAs (R-HSA-426496)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Neurophilin interactions with VEGF and VEGFR (R-HSA-194306)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
PLCG1 events in ERBB2 signaling (R-HSA-1251932)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Glycoprotein hormones (R-HSA-209822)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
TICAM1 deficiency - HSE (R-HSA-5602566)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
NOTCH4 Intracellular Domain Regulates Transcription (R-HSA-9013695)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Vitamin C (ascorbate) metabolism (R-HSA-196836)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Ubiquinol biosynthesis (R-HSA-2142789)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 (R-HSA-5140745)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Assembly of active LPL and LIPC lipase complexes (R-HSA-8963889)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Chylomicron assembly (R-HSA-8963888)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Transcription Initiation (R-HSA-76046)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
SDK interactions (R-HSA-373756)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling (R-HSA-975110)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
DEx/H-box helicases activate type I IFN and inflammatory cytokines production  (R-HSA-3134963)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
G alpha (z) signalling events (R-HSA-418597)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
Nephrin family interactions (R-HSA-373753)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
MPS IV - Morquio syndrome B (R-HSA-2206308)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II Transcription Initiation And Promoter Clearance (R-HSA-76042)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
Netrin-1 signaling (R-HSA-373752)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
MPS IIIA - Sanfilippo syndrome A (R-HSA-2206307)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Meiosis (R-HSA-1500620)	86	0	.45	-	 < 0.01	1.00E00	1.00E00
MPS IIID - Sanfilippo syndrome D (R-HSA-2206305)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
ADP signalling through P2Y purinoceptor 1 (R-HSA-418592)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Small interfering RNA (siRNA) biogenesis (R-HSA-426486)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Activation, translocation and oligomerization of BAX (R-HSA-114294)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
MPS I - Hurler syndrome (R-HSA-2206302)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Gastrin-CREB signalling pathway via PKC and MAPK (R-HSA-881907)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Downstream signal transduction (R-HSA-186763)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Prolonged ERK activation events (R-HSA-169893)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Transport of vitamins, nucleosides, and related molecules (R-HSA-425397)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Enzymatic degradation of Dopamine by monoamine oxidase (R-HSA-379398)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Enzymatic degradation of dopamine by COMT (R-HSA-379397)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Inhibition of TSC complex formation by PKB (R-HSA-165181)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Triglyceride metabolism (R-HSA-8979227)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 (R-HSA-933543)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Synthesis of 15-eicosatetraenoic acid derivatives (R-HSA-2142770)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
TRAF6 mediated NF-kB activation (R-HSA-933542)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Cation-coupled Chloride cotransporters (R-HSA-426117)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
TRAF6 mediated IRF7 activation (R-HSA-933541)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
LGI-ADAM interactions (R-HSA-5682910)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Downregulation of ERBB2:ERBB3 signaling (R-HSA-1358803)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Stimuli-sensing channels (R-HSA-2672351)	106	0	.56	-	 < 0.01	1.00E00	1.00E00
Mtb iron assimilation by chelation (R-HSA-1222449)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Organic anion transporters (R-HSA-428643)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Vitamin B1 (thiamin) metabolism (R-HSA-196819)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Neurotoxicity of clostridium toxins (R-HSA-168799)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Bicarbonate transporters (R-HSA-425381)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Synthesis of Ketone Bodies (R-HSA-77111)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
G beta:gamma signalling through PLC beta (R-HSA-418217)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Synthesis of bile acids and bile salts (R-HSA-192105)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
COPII-mediated vesicle transport (R-HSA-204005)	68	0	.36	-	 < 0.01	1.00E00	1.00E00
Retinoid cycle disease events (R-HSA-2453864)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Organic cation/anion/zwitterion transport (R-HSA-549132)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
PI and PC transport between ER and Golgi membranes (R-HSA-1483196)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Utilization of Ketone Bodies (R-HSA-77108)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Synthesis of PC (R-HSA-1483191)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Sema4D in semaphorin signaling (R-HSA-400685)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
AKT-mediated inactivation of FOXO1A (R-HSA-211163)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Metabolism of fat-soluble vitamins (R-HSA-6806667)	48	0	.25	-	 < 0.01	1.00E00	1.00E00
Rhesus glycoproteins mediate ammonium transport. (R-HSA-444411)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
PDE3B signalling (R-HSA-165160)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Metabolism of vitamin K (R-HSA-6806664)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers (R-HSA-983695)	94	0	.49	-	 < 0.01	1.00E00	1.00E00
ABC transporters in lipid homeostasis (R-HSA-1369062)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Digestion of dietary lipid (R-HSA-192456)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Organic cation transport (R-HSA-549127)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Nonsense-Mediated Decay (NMD) (R-HSA-927802)	115	0	.60	-	 < 0.01	1.00E00	1.00E00
G1/S-Specific Transcription (R-HSA-69205)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Scavenging of heme from plasma (R-HSA-2168880)	74	0	.39	-	 < 0.01	1.00E00	1.00E00
Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes (R-HSA-69200)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Synthesis And Processing Of GAG, GAGPOL Polyproteins (R-HSA-174495)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
mTOR signalling (R-HSA-165159)	40	0	.21	-	 < 0.01	1.00E00	1.00E00
Activation of AKT2 (R-HSA-165158)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Transcriptional activation of p53 responsive genes   (R-HSA-69560)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Membrane binding and targetting of GAG proteins (R-HSA-174490)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4) (R-HSA-5688890)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
VEGFA-VEGFR2 Pathway (R-HSA-4420097)	95	0	.50	-	 < 0.01	1.00E00	1.00E00
Regulation of Complement cascade (R-HSA-977606)	110	0	.58	-	 < 0.01	1.00E00	1.00E00
Erythrocytes take up carbon dioxide and release oxygen (R-HSA-1237044)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Keratinization (R-HSA-6805567)	217	0	1.14	-	 < 0.01	6.33E-01	1.00E00
Sulfur amino acid metabolism (R-HSA-1614635)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD) (R-HSA-5579032)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD) (R-HSA-5579031)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP19A1 causes Aromatase excess syndrome (AEXS) (R-HSA-5579030)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest (R-HSA-6804116)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain (R-HSA-6804115)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest (R-HSA-6804114)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Endosomal Sorting Complex Required For Transport (ESCRT) (R-HSA-917729)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Assembly of collagen fibrils and other multimeric structures (R-HSA-2022090)	60	0	.31	-	 < 0.01	1.00E00	1.00E00
Ketone body metabolism (R-HSA-74182)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective MPDU1 causes MPDU1-CDG (CDG-1f) (R-HSA-4687000)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Conjugation of carboxylic acids (R-HSA-159424)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Removal of aminoterminal propeptides from gamma-carboxylated proteins (R-HSA-159782)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Cell-Cell communication (R-HSA-1500931)	127	0	.67	-	 < 0.01	1.00E00	1.00E00
Metabolic disorders of biological oxidation enzymes (R-HSA-5579029)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Integration of viral DNA into host genomic DNA (R-HSA-175567)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5) (R-HSA-5579028)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B) (R-HSA-5579027)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Chondroitin sulfate/dermatan sulfate metabolism (R-HSA-1793185)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR) (R-HSA-5579026)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD) (R-HSA-5579024)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Neurodegenerative Diseases (R-HSA-8863678)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Defective GGT1 causes Glutathionuria (GLUTH) (R-HSA-5579022)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3) (R-HSA-5579021)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD) (R-HSA-5579020)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
N-glycan trimming in the ER and Calnexin/Calreticulin cycle (R-HSA-532668)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Interleukin-6 family signaling (R-HSA-6783589)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Interleukin-20 family signaling (R-HSA-8854691)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 (R-HSA-1362300)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Recycling of bile acids and salts (R-HSA-159418)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
RHO GTPases activate IQGAPs (R-HSA-5626467)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Dual Incision in GG-NER (R-HSA-5696400)	41	0	.21	-	 < 0.01	1.00E00	1.00E00
Role of LAT2/NTAL/LAB on calcium mobilization (R-HSA-2730905)	75	0	.39	-	 < 0.01	1.00E00	1.00E00
Intrinsic Pathway for Apoptosis (R-HSA-109606)	43	0	.23	-	 < 0.01	1.00E00	1.00E00
Interleukin-18 signaling (R-HSA-9012546)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Dual incision in TC-NER (R-HSA-6782135)	65	0	.34	-	 < 0.01	1.00E00	1.00E00
Platelet sensitization by LDL (R-HSA-432142)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Defective FMO3 causes Trimethylaminuria (TMAU) (R-HSA-5579019)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Pre-NOTCH Processing in the Endoplasmic Reticulum (R-HSA-1912399)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4) (R-HSA-5579017)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective UGT1A4 causes hyperbilirubinemia (R-HSA-5579016)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA) (R-HSA-5579015)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Role of second messengers in netrin-1 signaling (R-HSA-418890)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion (R-HSA-434316)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A) (R-HSA-5579014)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3) (R-HSA-5579013)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective MAOA causes Brunner syndrome (BRUNS) (R-HSA-5579012)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56) (R-HSA-5579011)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP24A1 causes Hypercalcemia, infantile (HCAI) (R-HSA-5579010)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Chromatin modifying enzymes (R-HSA-3247509)	241	0	1.26	-	 < 0.01	6.40E-01	1.00E00
Transcriptional  activation of  cell cycle inhibitor p21  (R-HSA-69895)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Hydrolysis of LPE (R-HSA-1483152)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Transcriptional Regulation by E2F6 (R-HSA-8953750)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
Peroxisomal lipid metabolism (R-HSA-390918)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Pentose phosphate pathway disease (R-HSA-6791465)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
FGFR1 ligand binding and activation (R-HSA-190242)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Synthesis of 12-eicosatetraenoic acid derivatives (R-HSA-2142712)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P (R-HSA-6791462)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
via Dependence Receptors in the absence of ligand (R-HSA-418889)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
FGFR2 ligand binding and activation (R-HSA-190241)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
RPIA deficiency: failed conversion of RU5P to R5P (R-HSA-6791461)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Digestion of dietary carbohydrate (R-HSA-189085)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus (R-HSA-159763)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Netrin mediated repulsion signals (R-HSA-418886)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
DCC mediated attractive signaling (R-HSA-418885)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency) (R-HSA-5579009)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective ACY1 causes encephalopathy (R-HSA-5579007)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Activation of anterior HOX genes in hindbrain development during early embryogenesis (R-HSA-5617472)	91	0	.48	-	 < 0.01	1.00E00	1.00E00
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency) (R-HSA-5579006)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5) (R-HSA-5579005)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
mTORC1-mediated signalling (R-HSA-166208)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4) (R-HSA-5579004)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
TGFBR2 Kinase Domain Mutants in Cancer (R-HSA-3645790)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Cysteine formation from homocysteine (R-HSA-1614603)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective UGT1A1 causes hyperbilirubinemia (R-HSA-5579002)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of PG (R-HSA-1483148)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Intestinal infectious diseases (R-HSA-8942233)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective CYP1B1 causes Glaucoma (R-HSA-5579000)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
TFAP2 (AP-2) family regulates transcription of cell cycle factors (R-HSA-8866911)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors (R-HSA-8866910)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Transcription (R-HSA-74158)	41	0	.21	-	 < 0.01	1.00E00	1.00E00
Reproduction (R-HSA-1474165)	112	0	.59	-	 < 0.01	1.00E00	1.00E00
FGFR3 ligand binding and activation (R-HSA-190239)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
RAB geranylgeranylation (R-HSA-8873719)	65	0	.34	-	 < 0.01	1.00E00	1.00E00
TICAM1-dependent activation of IRF3/IRF7 (R-HSA-9013973)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Signaling by NOTCH2 (R-HSA-1980145)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
PLC beta mediated events (R-HSA-112043)	44	0	.23	-	 < 0.01	1.00E00	1.00E00
G-protein mediated events (R-HSA-112040)	45	0	.24	-	 < 0.01	1.00E00	1.00E00
Synthesis of Lipoxins (LX) (R-HSA-2142700)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Metabolism of nitric oxide (R-HSA-202131)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Selenocysteine synthesis (R-HSA-2408557)	93	0	.49	-	 < 0.01	1.00E00	1.00E00
Protein ubiquitination (R-HSA-8852135)	74	0	.39	-	 < 0.01	1.00E00	1.00E00
Activation of the TFAP2 (AP-2) family of transcription factors (R-HSA-8866907)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia (R-HSA-5678420)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
TFAP2 (AP-2) family regulates transcription of other transcription factors (R-HSA-8866906)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Methylation of MeSeH for excretion (R-HSA-2408552)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Negative regulation of activity of TFAP2 (AP-2) family transcription factors (R-HSA-8866904)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se (R-HSA-2408550)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
RHO GTPases Activate Rhotekin and Rhophilins (R-HSA-5666185)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Defects in biotin (Btn) metabolism (R-HSA-3323169)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5) (R-HSA-5688849)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Telomere Maintenance (R-HSA-157579)	63	0	.33	-	 < 0.01	1.00E00	1.00E00
Thromboxane signalling through TP receptor (R-HSA-428930)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation (R-HSA-1474151)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Mitochondrial ABC transporters (R-HSA-1369007)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
SLIT2:ROBO1 increases RHOA activity (R-HSA-8985586)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Glycogen synthesis (R-HSA-3322077)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Unwinding of DNA (R-HSA-176974)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
PKA activation in glucagon signalling (R-HSA-164378)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Gamma-carboxylation of protein precursors (R-HSA-159740)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Melanin biosynthesis (R-HSA-5662702)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1 (R-HSA-5678771)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Removal of the Flap Intermediate from the C-strand (R-HSA-174437)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS) (R-HSA-5633231)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Mitochondrial transcription initiation (R-HSA-163282)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
TLR3-mediated TICAM1-dependent programmed cell death (R-HSA-9013957)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Response to metal ions (R-HSA-5660526)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Telomere C-strand synthesis initiation (R-HSA-174430)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Clathrin-mediated endocytosis (R-HSA-8856828)	138	0	.72	-	 < 0.01	1.00E00	1.00E00
Defective SLC7A9 causes cystinuria (CSNU) (R-HSA-5660883)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Cargo recognition for clathrin-mediated endocytosis (R-HSA-8856825)	98	0	.51	-	 < 0.01	1.00E00	1.00E00
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway (R-HSA-5676594)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Glycerophospholipid catabolism (R-HSA-6814848)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Formation of RNA Pol II elongation complex  (R-HSA-112382)	61	0	.32	-	 < 0.01	1.00E00	1.00E00
Meiotic synapsis (R-HSA-1221632)	58	0	.30	-	 < 0.01	1.00E00	1.00E00
Choline catabolism (R-HSA-6798163)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Hydrolysis of LPC (R-HSA-1483115)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Regulation of gap junction activity (R-HSA-191650)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Caspase-mediated cleavage of cytoskeletal proteins (R-HSA-264870)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of DHA-derived sulfido conjugates (R-HSA-9026395)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective ALG8 causes ALG8-CDG (CDG-1h) (R-HSA-4724325)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
MET Receptor Activation (R-HSA-6806942)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
ADP signalling through P2Y purinoceptor 12 (R-HSA-392170)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Signaling by NOTCH3 (R-HSA-9012852)	48	0	.25	-	 < 0.01	1.00E00	1.00E00
Glycogen storage disease type 0 (liver GYS2) (R-HSA-3858516)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Myoclonic epilepsy of Lafora (R-HSA-3785653)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Cell death signalling via NRAGE, NRIF and NADE (R-HSA-204998)	76	0	.40	-	 < 0.01	1.00E00	1.00E00
Dissolution of Fibrin Clot (R-HSA-75205)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Selenoamino acid metabolism (R-HSA-2408522)	116	0	.61	-	 < 0.01	1.00E00	1.00E00
Interleukin-6 signaling (R-HSA-1059683)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Synthesis of IPs in the nucleus (R-HSA-1855191)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Metalloprotease DUBs (R-HSA-5689901)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
c-src mediated regulation of Cx43 function and closure of gap junctions (R-HSA-191647)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Telomere C-strand (Lagging Strand) Synthesis (R-HSA-174417)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Synthesis of PS (R-HSA-1483101)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Processive synthesis on the C-strand of the telomere (R-HSA-174414)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Signaling by NTRKs (R-HSA-166520)	97	0	.51	-	 < 0.01	1.00E00	1.00E00
Cargo concentration in the ER (R-HSA-5694530)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Downregulation of SMAD2/3:SMAD4 transcriptional activity (R-HSA-2173795)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Polymerase switching on the C-strand of the telomere (R-HSA-174411)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) (R-HSA-2173791)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Activity through Methylation (R-HSA-6804760)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B (R-HSA-5682294)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC7A7 causes lysinuric protein intolerance (LPI) (R-HSA-5660862)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
SeMet incorporation into proteins (R-HSA-2408517)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Hypusine synthesis from eIF5A-lysine (R-HSA-204626)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective ALG11 causes ALG11-CDG (CDG-1p) (R-HSA-4551295)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of IP2, IP, and Ins in the cytosol (R-HSA-1855183)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Regulation of necroptotic cell death (R-HSA-5675482)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Metabolism of Angiotensinogen to Angiotensins (R-HSA-2022377)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Activity through Association with Co-factors (R-HSA-6804759)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
TGF-beta receptor signaling activates SMADs (R-HSA-2173789)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Activity through Acetylation (R-HSA-6804758)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7) (R-HSA-5683371)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Downregulation of TGF-beta receptor signaling (R-HSA-2173788)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Degradation (R-HSA-6804757)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Condensation of Prophase Chromosomes (R-HSA-2299718)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Activity through Phosphorylation (R-HSA-6804756)	92	0	.48	-	 < 0.01	1.00E00	1.00E00
Glutathione synthesis and recycling (R-HSA-174403)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Regulation of TP53 Expression (R-HSA-6804754)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
RUNX3 Regulates Immune Response and Cell Migration (R-HSA-8949275)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Binding and Uptake of Ligands by Scavenger Receptors (R-HSA-2173782)	102	0	.53	-	 < 0.01	1.00E00	1.00E00
Synthesis of bile acids and bile salts via 27-hydroxycholesterol (R-HSA-193807)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Nitric oxide stimulates guanylate cyclase (R-HSA-392154)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
A tetrasaccharide linker sequence is required for GAG synthesis (R-HSA-1971475)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
PI5P Regulates TP53 Acetylation (R-HSA-6811555)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Interleukin-37 signaling (R-HSA-9008059)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Hormone ligand-binding receptors (R-HSA-375281)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Metabolism of ingested SeMet, Sec, MeSec into H2Se (R-HSA-2408508)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Amine ligand-binding receptors (R-HSA-375280)	43	0	.23	-	 < 0.01	1.00E00	1.00E00
Mitochondrial translation termination (R-HSA-5419276)	88	0	.46	-	 < 0.01	1.00E00	1.00E00
SHC1 events in ERBB2 signaling (R-HSA-1250196)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Electron transport from NADPH to Ferredoxin (R-HSA-2395516)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
t(4;14) translocations of FGFR3 (R-HSA-2033515)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Sodium/Proton exchangers (R-HSA-425986)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
FGFR3 mutant receptor activation (R-HSA-2033514)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
YAP1- and WWTR1 (TAZ)-stimulated gene expression (R-HSA-2032785)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Generation of second messenger molecules (R-HSA-202433)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
Translocation of ZAP-70 to Immunological synapse (R-HSA-202430)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Cell-cell junction organization (R-HSA-421270)	64	0	.34	-	 < 0.01	1.00E00	1.00E00
Disinhibition of SNARE formation (R-HSA-114516)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Synthesis of pyrophosphates in the cytosol (R-HSA-1855167)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Plasmalogen biosynthesis (R-HSA-75896)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Calnexin/calreticulin cycle (R-HSA-901042)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
TNF signaling (R-HSA-75893)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Unblocking of NMDA receptor, glutamate binding and activation (R-HSA-438066)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Post NMDA receptor activation events (R-HSA-438064)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
NTF4 activates NTRK2 (TRKB) signaling (R-HSA-9026357)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Phosphorylation of CD3 and TCR zeta chains (R-HSA-202427)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Phenylalanine and tyrosine catabolism (R-HSA-71182)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
ROBO receptors bind AKAP5 (R-HSA-9010642)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Trafficking of GluR2-containing AMPA receptors (R-HSA-416993)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Activated NTRK3 signals through PI3K (R-HSA-9603381)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Formation of the Early Elongation Complex (R-HSA-113418)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Regulation of signaling by NODAL (R-HSA-1433617)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
ER Quality Control Compartment (ERQC) (R-HSA-901032)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
XAV939 inhibits tankyrase, stabilizing AXIN (R-HSA-5545619)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
SUMOylation of transcription cofactors (R-HSA-3899300)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Diseases associated with visual transduction (R-HSA-2474795)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Listeria monocytogenes entry into host cells (R-HSA-8876384)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
AKT phosphorylates targets in the nucleus (R-HSA-198693)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Gap junction degradation (R-HSA-190873)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Transport of connexons to the plasma membrane (R-HSA-190872)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective B3GALT6 causes EDSP2 and SEMDJL1 (R-HSA-4420332)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
WNT mediated activation of DVL (R-HSA-201688)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Synthesis of very long-chain fatty acyl-CoAs (R-HSA-75876)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
EGFR Transactivation by Gastrin (R-HSA-2179392)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Gap junction trafficking and regulation (R-HSA-157858)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
Formation of ATP by chemiosmotic coupling (R-HSA-163210)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Activation of NIMA Kinases NEK9, NEK6, NEK7 (R-HSA-2980767)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Nuclear Envelope Breakdown (R-HSA-2980766)	46	0	.24	-	 < 0.01	1.00E00	1.00E00
Neurotransmitter receptors and postsynaptic signal transmission (R-HSA-112314)	148	0	.78	-	 < 0.01	1.00E00	1.00E00
Butyrophilin (BTN) family interactions (R-HSA-8851680)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
AKT phosphorylates targets in the cytosol (R-HSA-198323)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Neurotransmitter clearance (R-HSA-112311)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Gap junction assembly (R-HSA-190861)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
Miscellaneous transport and binding events (R-HSA-5223345)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Defective SLC5A2 causes renal glucosuria (GLYS1) (R-HSA-5658208)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Initiation of Nuclear Envelope Reformation (R-HSA-2995383)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ) (R-HSA-5683329)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Signaling by MST1 (R-HSA-8852405)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Interleukin receptor SHC signaling (R-HSA-912526)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. (R-HSA-163200)	123	0	.64	-	 < 0.01	1.00E00	1.00E00
Triglyceride catabolism (R-HSA-163560)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Toxicity of botulinum toxin type E (BoNT/E) (R-HSA-5250992)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Stimulation of the cell death response by PAK-2p34 (R-HSA-211736)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Presynaptic depolarization and calcium channel opening (R-HSA-112308)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Transmission across Electrical Synapses  (R-HSA-112307)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Electric Transmission Across Gap Junctions (R-HSA-112303)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Uptake and actions of bacterial toxins (R-HSA-5339562)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) (R-HSA-5358606)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Classical antibody-mediated complement activation (R-HSA-173623)	70	0	.37	-	 < 0.01	1.00E00	1.00E00
Regulation of TLR by endogenous ligand (R-HSA-5686938)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3) (R-HSA-5683678)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Regulation of PLK1 Activity at G2/M Transition (R-HSA-2565942)	85	0	.45	-	 < 0.01	1.00E00	1.00E00
Extension of Telomeres (R-HSA-180786)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
RHO GTPases activate KTN1 (R-HSA-5625970)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Toxicity of botulinum toxin type G (BoNT/G) (R-HSA-5250989)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Regulation of PAK-2p34 activity by PS-GAP/RHG10 (R-HSA-211728)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Mitochondrial calcium ion transport (R-HSA-8949215)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Toxicity of tetanus toxin (TeNT) (R-HSA-5250982)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Toxicity of botulinum toxin type F (BoNT/F) (R-HSA-5250981)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
AMER1 mutants destabilize the destruction complex (R-HSA-4839748)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Processing and activation of SUMO (R-HSA-3215018)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
truncated APC mutants destabilize the destruction complex (R-HSA-4839744)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex (R-HSA-4839743)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
RPIA deficiency: failed conversion of R5P to RU5P (R-HSA-5659996)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane (R-HSA-190840)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
G beta:gamma signalling through PI3Kgamma (R-HSA-392451)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Basigin interactions (R-HSA-210991)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
PECAM1 interactions (R-HSA-210990)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Toxicity of botulinum toxin type C (BoNT/C) (R-HSA-5250971)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Glycosphingolipid metabolism (R-HSA-1660662)	45	0	.24	-	 < 0.01	1.00E00	1.00E00
VEGF binds to VEGFR leading to receptor dimerization (R-HSA-195399)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Sphingolipid de novo biosynthesis (R-HSA-1660661)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models (R-HSA-8862803)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
AXIN mutants destabilize the destruction complex, activating WNT signaling (R-HSA-4839735)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM) (R-HSA-5656364)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Abortive And Retractive Initiation (R-HSA-749476)	41	0	.21	-	 < 0.01	1.00E00	1.00E00
PCNA-Dependent Long Patch Base Excision Repair (R-HSA-5651801)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Golgi Associated Vesicle Biogenesis (R-HSA-432722)	54	0	.28	-	 < 0.01	1.00E00	1.00E00
Lysosome Vesicle Biogenesis (R-HSA-432720)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Cholesterol biosynthesis via lathosterol (R-HSA-6807062)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Toxicity of botulinum toxin type A (BoNT/A) (R-HSA-5250968)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Resolution of Sister Chromatid Cohesion (R-HSA-2500257)	122	0	.64	-	 < 0.01	1.00E00	1.00E00
Gap junction trafficking (R-HSA-190828)	48	0	.25	-	 < 0.01	1.00E00	1.00E00
Cytosolic iron-sulfur cluster assembly (R-HSA-2564830)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Transport of connexins along the secretory pathway (R-HSA-190827)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Chromatin organization (R-HSA-4839726)	241	0	1.26	-	 < 0.01	6.40E-01	1.00E00
Interleukin-17 signaling (R-HSA-448424)	71	0	.37	-	 < 0.01	1.00E00	1.00E00
Elevation of cytosolic Ca2+ levels (R-HSA-139853)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
SMAD2/3 Phosphorylation Motif Mutants in Cancer (R-HSA-3304356)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Pregnenolone biosynthesis (R-HSA-196108)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Processing of Capped Intron-Containing Pre-mRNA (R-HSA-72203)	237	0	1.24	-	 < 0.01	6.39E-01	1.00E00
Transport of Mature Transcript to Cytoplasm (R-HSA-72202)	79	0	.41	-	 < 0.01	1.00E00	1.00E00
Toxicity of botulinum toxin type B (BoNT/B) (R-HSA-5250958)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
mRNA Editing: C to U Conversion (R-HSA-72200)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Signaling by TGF-beta Receptor Complex in Cancer (R-HSA-3304351)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Toxicity of botulinum toxin type D (BoNT/D) (R-HSA-5250955)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 (R-HSA-964827)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Retinoid metabolism disease events (R-HSA-6809583)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Negative regulators of DDX58/IFIH1 signaling (R-HSA-936440)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
MPS II - Hunter syndrome (R-HSA-2206296)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Attachment of GPI anchor to uPAR (R-HSA-162791)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
MPS VII - Sly syndrome (R-HSA-2206292)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Polo-like kinase mediated events (R-HSA-156711)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
MPS IIIC - Sanfilippo syndrome C (R-HSA-2206291)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
MPS IV - Morquio syndrome A (R-HSA-2206290)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Regulation of thyroid hormone activity (R-HSA-350864)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Cholesterol biosynthesis via desmosterol (R-HSA-6807047)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Loss of Function of SMAD2/3 in Cancer (R-HSA-3304349)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Interleukin-35 Signalling (R-HSA-8984722)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Loss of Function of SMAD4 in Cancer (R-HSA-3304347)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Nuclear import of Rev protein (R-HSA-180746)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Beta-oxidation of very long chain fatty acids (R-HSA-390247)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
STAT6-mediated induction of chemokines (R-HSA-3249367)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Negative epigenetic regulation of rRNA expression (R-HSA-5250941)	78	0	.41	-	 < 0.01	1.00E00	1.00E00
Regulation of cortical dendrite branching (R-HSA-8985801)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
MPS VI - Maroteaux-Lamy syndrome (R-HSA-2206285)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
MPS IIIB - Sanfilippo syndrome B (R-HSA-2206282)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Mucopolysaccharidoses (R-HSA-2206281)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
MPS IX - Natowicz syndrome (R-HSA-2206280)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Adenylate cyclase inhibitory pathway (R-HSA-170670)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Signal transduction by L1 (R-HSA-445144)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Regulation by c-FLIP (R-HSA-3371378)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Opioid Signalling (R-HSA-111885)	81	0	.42	-	 < 0.01	1.00E00	1.00E00
The role of Nef in HIV-1 replication and disease pathogenesis (R-HSA-164952)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Galactose catabolism (R-HSA-70370)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Receptor Mediated Mitophagy (R-HSA-8934903)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
rRNA processing in the nucleus and cytosol (R-HSA-8868773)	191	0	1.00	-	 < 0.01	6.29E-01	1.00E00
Defective GGT1 causes Glutathionuria (GLUTH) (R-HSA-9035968)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Pink/Parkin Mediated Mitophagy (R-HSA-5205685)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
CD209 (DC-SIGN) signaling (R-HSA-5621575)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Deposition of new CENPA-containing nucleosomes at the centromere (R-HSA-606279)	54	0	.28	-	 < 0.01	1.00E00	1.00E00
Pyrimidine catabolism (R-HSA-73621)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Adenylate cyclase activating pathway (R-HSA-170660)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
RUNX2 regulates osteoblast differentiation (R-HSA-8940973)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Nef and signal transduction (R-HSA-164944)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase III Transcription Termination (R-HSA-73980)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Nucleotide salvage (R-HSA-8956321)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Nucleobase biosynthesis (R-HSA-8956320)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Nef mediated downregulation of MHC class I complex cell surface expression (R-HSA-164940)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
rRNA processing in the mitochondrion (R-HSA-8868766)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Lipid particle organization (R-HSA-8964572)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
B-WICH complex positively regulates rRNA expression (R-HSA-5250924)	59	0	.31	-	 < 0.01	1.00E00	1.00E00
Vitamin D (calciferol) metabolism (R-HSA-196791)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Diseases of metabolism (R-HSA-5668914)	104	0	.54	-	 < 0.01	1.00E00	1.00E00
Other interleukin signaling (R-HSA-449836)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Recycling pathway of L1 (R-HSA-437239)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
Synthesis of UDP-N-acetyl-glucosamine (R-HSA-446210)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective EXT1 causes exostoses 1, TRPS2 and CHDS (R-HSA-3656253)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Nucleobase catabolism (R-HSA-8956319)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Nef mediated downregulation of CD28 cell surface expression (R-HSA-164939)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Pyrimidine salvage (R-HSA-73614)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters (R-HSA-164938)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Activated NTRK3 signals through RAS (R-HSA-9034864)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Amine-derived hormones (R-HSA-209776)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Fructose catabolism (R-HSA-70350)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Inhibition of PKR (R-HSA-169131)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates estrogen receptor mediated transcription (R-HSA-8931987)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
DNA strand elongation (R-HSA-69190)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Release of Hh-Np from the secreting cell (R-HSA-5362798)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Reuptake of GABA (R-HSA-888593)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Positive epigenetic regulation of rRNA expression (R-HSA-5250913)	74	0	.39	-	 < 0.01	1.00E00	1.00E00
Gamma carboxylation, hypusine formation and arylsulfatase activation (R-HSA-163841)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Coenzyme A biosynthesis (R-HSA-196783)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
GABA synthesis, release, reuptake and degradation (R-HSA-888590)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Biotin transport and metabolism (R-HSA-196780)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Synthesis of GDP-mannose (R-HSA-446205)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective HEXB causes GM2G2 (R-HSA-3656248)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Signaling by NTRK2 (TRKB) (R-HSA-9006115)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
MET activates RAP1 and RAC1 (R-HSA-8875555)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) (R-HSA-3656244)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective ST3GAL3 causes MCT12 and EIEE15 (R-HSA-3656243)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Lagging Strand Synthesis (R-HSA-69186)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Negative regulation of MET activity (R-HSA-6807004)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
rRNA modification in the nucleus and cytosol (R-HSA-6790901)	60	0	.31	-	 < 0.01	1.00E00	1.00E00
Processive synthesis on the lagging strand (R-HSA-69183)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
RNA Pol II CTD phosphorylation and interaction with CE (R-HSA-77075)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Phosphate bond hydrolysis by NUDT proteins (R-HSA-2393930)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism (R-HSA-6788656)	46	0	.24	-	 < 0.01	1.00E00	1.00E00
Apoptotic cleavage of cell adhesion  proteins (R-HSA-351906)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Defective EXT2 causes exostoses 2 (R-HSA-3656237)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective HEXA causes GM2G1 (R-HSA-3656234)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
MHC class II antigen presentation (R-HSA-2132295)	125	0	.65	-	 < 0.01	1.00E00	1.00E00
MyD88 deficiency (TLR2/4) (R-HSA-5602498)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Global Genome Nucleotide Excision Repair (GG-NER) (R-HSA-5696399)	84	0	.44	-	 < 0.01	1.00E00	1.00E00
Defective DPM2 causes DPM2-CDG (CDG-1u) (R-HSA-4719377)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Nucleotide Excision Repair (R-HSA-5696398)	110	0	.58	-	 < 0.01	1.00E00	1.00E00
Gap-filling DNA repair synthesis and ligation in GG-NER (R-HSA-5696397)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Activation of gene expression by SREBF (SREBP) (R-HSA-2426168)	40	0	.21	-	 < 0.01	1.00E00	1.00E00
Mitophagy (R-HSA-5205647)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Diseases of glycosylation (R-HSA-3781865)	141	0	.74	-	 < 0.01	1.00E00	1.00E00
Formation of Incision Complex in GG-NER (R-HSA-5696395)	43	0	.23	-	 < 0.01	1.00E00	1.00E00
DNA Damage Recognition in GG-NER (R-HSA-5696394)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Estrogen biosynthesis (R-HSA-193144)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Signaling by Leptin (R-HSA-2586552)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Protein-protein interactions at synapses (R-HSA-6794362)	87	0	.46	-	 < 0.01	1.00E00	1.00E00
NRIF signals cell death from the nucleus (R-HSA-205043)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Neurexins and neuroligins (R-HSA-6794361)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
Diseases associated with N-glycosylation of proteins (R-HSA-3781860)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Orexin and neuropeptides FF and QRFP bind to their respective receptors (R-HSA-389397)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Signaling by EGFR in Cancer (R-HSA-1643713)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Defective CHST6 causes MCDC1 (R-HSA-3656225)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933)	194	0	1.02	-	 < 0.01	6.30E-01	1.00E00
Proline catabolism (R-HSA-70688)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Pausing and recovery of HIV elongation (R-HSA-167290)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
ARMS-mediated activation (R-HSA-170984)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Phosphate bond hydrolysis by NTPDase proteins (R-HSA-8850843)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Removal of the Flap Intermediate (R-HSA-69166)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Formation of xylulose-5-phosphate (R-HSA-5661270)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
GABA synthesis (R-HSA-888568)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Metabolism of folate and pterines (R-HSA-196757)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Defective DPM3 causes DPM3-CDG (CDG-1o) (R-HSA-4719360)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Pyruvate metabolism and Citric Acid (TCA) cycle (R-HSA-71406)	54	0	.28	-	 < 0.01	1.00E00	1.00E00
Citric acid cycle (TCA cycle) (R-HSA-71403)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Interleukin-38 signaling (R-HSA-9007892)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
HIV elongation arrest and recovery (R-HSA-167287)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
Acyl chain remodelling of PG (R-HSA-1482925)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Arachidonate production from DAG (R-HSA-426048)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Acyl chain remodelling of PI (R-HSA-1482922)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Regulation of PTEN localization (R-HSA-8948747)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
IRF3 mediated activation of type 1 IFN (R-HSA-1606341)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Interleukin-1 processing (R-HSA-448706)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Resolution of Abasic Sites (AP sites) (R-HSA-73933)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway (R-HSA-73930)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
HS-GAG biosynthesis (R-HSA-2022928)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Transcription of E2F targets under negative control by DREAM complex (R-HSA-1362277)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Formation of editosomes by ADAR proteins (R-HSA-77042)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Dermatan sulfate biosynthesis (R-HSA-2022923)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Wax biosynthesis (R-HSA-8848584)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
NADE modulates death signalling (R-HSA-205025)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Synthesis of Hepoxilins (HX) and Trioxilins (TrX) (R-HSA-2142696)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Cobalamin (Cbl, vitamin B12) transport and metabolism (R-HSA-196741)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Synthesis of dolichyl-phosphate-glucose (R-HSA-480985)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of Leukotrienes (LT) and Eoxins (EX) (R-HSA-2142691)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
MET promotes cell motility (R-HSA-8875878)	40	0	.21	-	 < 0.01	1.00E00	1.00E00
Clathrin derived vesicle budding (R-HSA-421837)	72	0	.38	-	 < 0.01	1.00E00	1.00E00
Base-Excision Repair, AP Site Formation (R-HSA-73929)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Frs2-mediated activation (R-HSA-170968)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
MET interacts with TNS proteins (R-HSA-8875513)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Depyrimidination (R-HSA-73928)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Synthesis of glycosylphosphatidylinositol (GPI) (R-HSA-162710)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Depurination (R-HSA-73927)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Chemokine receptors bind chemokines (R-HSA-380108)	48	0	.25	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of E-series 18(R)-resolvins (R-HSA-9023661)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
TICAM1,TRAF6-dependent induction of TAK1 complex (R-HSA-9014325)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Mitochondrial Uncoupling Proteins (R-HSA-166187)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
The NLRP3 inflammasome (R-HSA-844456)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
The NLRP1 inflammasome (R-HSA-844455)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Inhibition of Signaling by Overexpressed EGFR (R-HSA-5638303)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
EPH-Ephrin signaling (R-HSA-2682334)	91	0	.48	-	 < 0.01	1.00E00	1.00E00
Circadian Clock (R-HSA-400253)	67	0	.35	-	 < 0.01	1.00E00	1.00E00
Signaling by Overexpressed Wild-Type EGFR in Cancer (R-HSA-5638302)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
NFG and proNGF binds to p75NTR (R-HSA-205017)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Establishment of Sister Chromatid Cohesion (R-HSA-2468052)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Synthesis of 5-eicosatetraenoic acids (R-HSA-2142688)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
MET activates PI3K/AKT signaling (R-HSA-8851907)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Hydroxycarboxylic acid-binding receptors (R-HSA-3296197)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II Pre-transcription Events (R-HSA-674695)	84	0	.44	-	 < 0.01	1.00E00	1.00E00
Striated Muscle Contraction (R-HSA-390522)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
Interconversion of nucleotide di- and triphosphates (R-HSA-499943)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding (R-HSA-6814122)	42	0	.22	-	 < 0.01	1.00E00	1.00E00
CD22 mediated BCR regulation (R-HSA-5690714)	67	0	.35	-	 < 0.01	1.00E00	1.00E00
ZBP1(DAI) mediated induction of type I IFNs (R-HSA-1606322)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Proton-coupled neutral amino acid transporters (R-HSA-428559)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
DNA Damage/Telomere Stress Induced Senescence (R-HSA-2559586)	61	0	.32	-	 < 0.01	1.00E00	1.00E00
Formation of Senescence-Associated Heterochromatin Foci (SAHF) (R-HSA-2559584)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Defective DHDDS causes retinitis pigmentosa 59 (R-HSA-4755609)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Latent infection of Homo sapiens with Mycobacterium tuberculosis (R-HSA-1222352)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
O-glycosylation of TSR domain-containing proteins (R-HSA-5173214)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Crosslinking of collagen fibrils (R-HSA-2243919)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Pyrophosphate hydrolysis (R-HSA-71737)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) (R-HSA-2142670)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Pyrimidine biosynthesis (R-HSA-500753)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Epigenetic regulation of gene expression (R-HSA-212165)	116	0	.61	-	 < 0.01	1.00E00	1.00E00
MyD88-independent TLR4 cascade  (R-HSA-166166)	97	0	.51	-	 < 0.01	1.00E00	1.00E00
Defective AVP causes neurohypophyseal diabetes insipidus (NDI) (R-HSA-9036092)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
PTK6 promotes HIF1A stabilization (R-HSA-8857538)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Thrombin signalling through proteinase activated receptors (PARs) (R-HSA-456926)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Metallothioneins bind metals (R-HSA-5661231)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Defective B3GAT3 causes JDSSDHD (R-HSA-3560801)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Inactivation of CDC42 and RAC1 (R-HSA-428543)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Regulation of commissural axon pathfinding by SLIT and ROBO (R-HSA-428542)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Activation of RAC1 (R-HSA-428540)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
NEP/NS2 Interacts with the Cellular Export Machinery (R-HSA-168333)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P (R-HSA-6791055)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Viral RNP Complexes in the Host Cell Nucleus (R-HSA-168330)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Mitochondrial biogenesis (R-HSA-1592230)	92	0	.48	-	 < 0.01	1.00E00	1.00E00
Tat-mediated elongation of the HIV-1 transcript (R-HSA-167246)	46	0	.24	-	 < 0.01	1.00E00	1.00E00
Glycogen storage disease type Ib (SLC37A4) (R-HSA-3229133)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Tat-mediated HIV elongation arrest and recovery (R-HSA-167243)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
Myogenesis (R-HSA-525793)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Abortive elongation of HIV-1 transcript in the absence of Tat (R-HSA-167242)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
TGFBR1 LBD Mutants in Cancer (R-HSA-3656535)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Degradation of cysteine and homocysteine (R-HSA-1614558)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Loss of Function of TGFBR1 in Cancer (R-HSA-3656534)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
TGFBR1 KD Mutants in Cancer (R-HSA-3656532)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Ovarian tumor domain proteases (R-HSA-5689896)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Urea cycle (R-HSA-70635)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
G2/M DNA replication checkpoint (R-HSA-69478)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Competing endogenous RNAs (ceRNAs) regulate PTEN translation (R-HSA-8948700)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
APC/C:Cdc20 mediated degradation of Cyclin B (R-HSA-174048)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Postsynaptic nicotinic acetylcholine receptors (R-HSA-622327)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Cholesterol biosynthesis (R-HSA-191273)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
RHO GTPases activate PAKs (R-HSA-5627123)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
G2/M DNA damage checkpoint (R-HSA-69473)	78	0	.41	-	 < 0.01	1.00E00	1.00E00
Presynaptic nicotinic acetylcholine receptors (R-HSA-622323)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Viral Messenger RNA Synthesis (R-HSA-168325)	40	0	.21	-	 < 0.01	1.00E00	1.00E00
Role of ABL in ROBO-SLIT signaling (R-HSA-428890)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Translesion synthesis by POLK (R-HSA-5655862)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Pausing and recovery of Tat-mediated HIV elongation (R-HSA-167238)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
Factors involved in megakaryocyte development and platelet production (R-HSA-983231)	157	0	.82	-	 < 0.01	1.00E00	1.00E00
Glycogen storage diseases (R-HSA-3229121)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Synthesis of PIPs in the nucleus (R-HSA-8847453)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Nef Mediated CD4 Down-regulation (R-HSA-167590)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
SUMOylation of DNA methylation proteins (R-HSA-4655427)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Leading Strand Synthesis (R-HSA-69109)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
TNFs bind their physiological receptors (R-HSA-5669034)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Nucleosome assembly (R-HSA-774815)	54	0	.28	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function (R-HSA-8936459)	66	0	.35	-	 < 0.01	1.00E00	1.00E00
RHO GTPases Activate ROCKs (R-HSA-5627117)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Collagen biosynthesis and modifying enzymes (R-HSA-1650814)	67	0	.35	-	 < 0.01	1.00E00	1.00E00
RMTs methylate histone arginines (R-HSA-3214858)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA (R-HSA-450385)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Assembly of Viral Components at the Budding Site (R-HSA-168316)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
MTF1 activates gene expression (R-HSA-5660489)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Inflammasomes (R-HSA-622312)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Inhibition of Host mRNA Processing and RNA Silencing (R-HSA-168315)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Beta oxidation of butanoyl-CoA to acetyl-CoA (R-HSA-77352)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Rev-mediated nuclear export of HIV RNA (R-HSA-165054)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Beta oxidation of hexanoyl-CoA to butanoyl-CoA (R-HSA-77350)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Macroautophagy (R-HSA-1632852)	68	0	.36	-	 < 0.01	1.00E00	1.00E00
cGMP effects (R-HSA-418457)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Digestion and absorption (R-HSA-8963743)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Josephin domain DUBs (R-HSA-5689877)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Assembly Of The HIV Virion (R-HSA-175474)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Amino acid synthesis and interconversion (transamination) (R-HSA-70614)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Synthesis of CL (R-HSA-1483076)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Glycosaminoglycan metabolism (R-HSA-1630316)	123	0	.64	-	 < 0.01	1.00E00	1.00E00
HATs acetylate histones (R-HSA-3214847)	108	0	.57	-	 < 0.01	1.00E00	1.00E00
Beta oxidation of octanoyl-CoA to hexanoyl-CoA (R-HSA-77348)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Fructose biosynthesis (R-HSA-5652227)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal (R-HSA-141444)	92	0	.48	-	 < 0.01	1.00E00	1.00E00
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA (R-HSA-77346)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Interferon alpha/beta signaling (R-HSA-909733)	67	0	.35	-	 < 0.01	1.00E00	1.00E00
UNC93B1 deficiency - HSE (R-HSA-5602415)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
HDMs demethylate histones (R-HSA-3214842)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
PKMTs methylate histone lysines (R-HSA-3214841)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
Transport of organic anions (R-HSA-879518)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
TLR3 deficiency - HSE (R-HSA-5602410)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective ALG6 causes ALG6-CDG (CDG-1c) (R-HSA-4724289)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
TWIK-related spinal cord K+ channel (TRESK) (R-HSA-1299344)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
GRB2 events in EGFR signaling (R-HSA-179812)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Signalling to p38 via RIT and RIN (R-HSA-187706)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
mRNA decay by 3' to 5' exoribonuclease (R-HSA-429958)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Sodium-coupled sulphate, di- and tri-carboxylate transporters (R-HSA-433137)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Transferrin endocytosis and recycling (R-HSA-917977)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Inactivation of APC/C via direct inhibition of the APC/C complex (R-HSA-141430)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Complex I biogenesis (R-HSA-6799198)	55	0	.29	-	 < 0.01	1.00E00	1.00E00
Synthesis of bile acids and bile salts via 24-hydroxycholesterol (R-HSA-193775)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Metabolism of ingested MeSeO2H into MeSeH (R-HSA-5263617)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
NoRC negatively regulates rRNA expression (R-HSA-427413)	75	0	.39	-	 < 0.01	1.00E00	1.00E00
Passive transport by Aquaporins (R-HSA-432047)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Apoptosis induced DNA fragmentation (R-HSA-140342)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Deadenylation of mRNA (R-HSA-429947)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Vasopressin regulates renal water homeostasis via Aquaporins (R-HSA-432040)	43	0	.23	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Metabolic Genes (R-HSA-5628897)	83	0	.43	-	 < 0.01	1.00E00	1.00E00
Formation of HIV-1 elongation complex containing HIV-1 Tat (R-HSA-167200)	46	0	.24	-	 < 0.01	1.00E00	1.00E00
Glyoxylate metabolism and glycine degradation (R-HSA-389661)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Sulfide oxidation to sulfate (R-HSA-1614517)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
TRAIL  signaling (R-HSA-75158)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
FasL/ CD95L signaling (R-HSA-75157)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Apoptotic execution phase (R-HSA-75153)	51	0	.27	-	 < 0.01	1.00E00	1.00E00
Prostanoid ligand receptors (R-HSA-391908)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Leukotriene receptors (R-HSA-391906)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Diseases associated with O-glycosylation of proteins (R-HSA-3906995)	69	0	.36	-	 < 0.01	1.00E00	1.00E00
Amplification of signal from the kinetochores (R-HSA-141424)	92	0	.48	-	 < 0.01	1.00E00	1.00E00
Eicosanoid ligand-binding receptors (R-HSA-391903)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Glutamate binding, activation of AMPA receptors and synaptic plasticity (R-HSA-399721)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Transport and synthesis of PAPS (R-HSA-174362)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Potassium transport channels (R-HSA-1296067)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways (R-HSA-168643)	54	0	.28	-	 < 0.01	1.00E00	1.00E00
Inwardly rectifying K+ channels (R-HSA-1296065)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
HCN channels (R-HSA-1296061)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Defects in vitamin and cofactor metabolism (R-HSA-3296482)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
G-protein activation (R-HSA-202040)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Digestion (R-HSA-8935690)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Cohesin Loading onto Chromatin (R-HSA-2470946)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Transport of glycerol from adipocytes to the liver by Aquaporins (R-HSA-432030)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Uptake and function of anthrax toxins (R-HSA-5210891)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Aquaporin-mediated transport (R-HSA-445717)	52	0	.27	-	 < 0.01	1.00E00	1.00E00
Trafficking of AMPA receptors (R-HSA-399719)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
HDACs deacetylate histones (R-HSA-3214815)	60	0	.31	-	 < 0.01	1.00E00	1.00E00
TBC/RABGAPs (R-HSA-8854214)	44	0	.23	-	 < 0.01	1.00E00	1.00E00
Defensins (R-HSA-1461973)	46	0	.24	-	 < 0.01	1.00E00	1.00E00
Activation of AMPA receptors (R-HSA-399710)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
NOD1/2 Signaling Pathway (R-HSA-168638)	35	0	.18	-	 < 0.01	1.00E00	1.00E00
Regulation of IFNG signaling (R-HSA-877312)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
G protein gated Potassium channels (R-HSA-1296059)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
TWIK-releated acid-sensitive K+ channel (TASK) (R-HSA-1299316)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Activation of the AP-1 family of transcription factors (R-HSA-450341)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA (R-HSA-77310)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Classical Kir channels (R-HSA-1296053)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Ca2+ activated K+ channels (R-HSA-1296052)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective ABCD1 causes adrenoleukodystrophy (ALD) (R-HSA-5684045)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Aflatoxin activation and detoxification (R-HSA-5423646)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
ERBB2 Regulates Cell Motility (R-HSA-6785631)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Regulation of RUNX1 Expression and Activity (R-HSA-8934593)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Hyaluronan uptake and degradation (R-HSA-2160916)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Dimerization of procaspase-8 (R-HSA-69416)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components (R-HSA-141405)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Synaptic adhesion-like molecules (R-HSA-8849932)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
NOTCH3 Intracellular Domain Regulates Transcription (R-HSA-9013508)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
NOTCH3 Activation and Transmission of Signal to the Nucleus (R-HSA-9013507)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Beta oxidation of palmitoyl-CoA to myristoyl-CoA (R-HSA-77305)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) (R-HSA-1299308)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Interferon gamma signaling (R-HSA-877300)	91	0	.48	-	 < 0.01	1.00E00	1.00E00
CDC6 association with the ORC:origin complex (R-HSA-68689)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Defects in cobalamin (B12) metabolism (R-HSA-3296469)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Gene Silencing by RNA (R-HSA-211000)	102	0	.53	-	 < 0.01	1.00E00	1.00E00
Activation of G protein gated Potassium channels (R-HSA-1296041)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
PI-3K cascade:FGFR3 (R-HSA-5654710)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Degradation of GABA (R-HSA-916853)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Deadenylation-dependent mRNA decay (R-HSA-429914)	56	0	.29	-	 < 0.01	1.00E00	1.00E00
Respiratory electron transport (R-HSA-611105)	100	0	.52	-	 < 0.01	1.00E00	1.00E00
Histidine catabolism (R-HSA-70921)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Beta defensins (R-HSA-1461957)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
tRNA processing in the nucleus (R-HSA-6784531)	53	0	.28	-	 < 0.01	1.00E00	1.00E00
Erythrocytes take up oxygen and release carbon dioxide (R-HSA-1247673)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Iron uptake and transport (R-HSA-917937)	58	0	.30	-	 < 0.01	1.00E00	1.00E00
Sodium/Calcium exchangers (R-HSA-425561)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1 (R-HSA-450321)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) (R-HSA-400511)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Downstream signaling of activated FGFR3 (R-HSA-5654708)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Retinoid metabolism and transport (R-HSA-975634)	44	0	.23	-	 < 0.01	1.00E00	1.00E00
FRS-mediated FGFR3 signaling (R-HSA-5654706)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
SHC-mediated cascade:FGFR3 (R-HSA-5654704)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
FRS-mediated FGFR2 signaling (R-HSA-5654700)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Activation of BH3-only proteins (R-HSA-114452)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Nef Mediated CD8 Down-regulation (R-HSA-182218)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
RHO GTPases Activate NADPH Oxidases (R-HSA-5668599)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
ATP sensitive Potassium channels (R-HSA-1296025)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Formation of the active cofactor, UDP-glucuronate (R-HSA-173599)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
CS/DS degradation (R-HSA-2024101)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Sema4D induced cell migration and growth-cone collapse (R-HSA-416572)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
Post-chaperonin tubulin folding pathway (R-HSA-389977)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of DPAn-3-derived maresins (R-HSA-9026290)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Ficolins bind to repetitive carbohydrate structures on the target cell surface (R-HSA-2855086)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Triglyceride biosynthesis (R-HSA-75109)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Activation, myristolyation of BID and translocation to mitochondria (R-HSA-75108)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Fatty acyl-CoA biosynthesis (R-HSA-75105)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
Activation of HOX genes during differentiation (R-HSA-5619507)	91	0	.48	-	 < 0.01	1.00E00	1.00E00
Regulation of KIT signaling (R-HSA-1433559)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
C6 deamination of adenosine (R-HSA-75102)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Creation of C4 and C2 activators (R-HSA-166786)	77	0	.40	-	 < 0.01	1.00E00	1.00E00
Signaling by SCF-KIT (R-HSA-1433557)	40	0	.21	-	 < 0.01	1.00E00	1.00E00
Trafficking of myristoylated proteins to the cilium (R-HSA-5624138)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
activated TAK1 mediates p38 MAPK activation (R-HSA-450302)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Transcriptional Regulation by TP53 (R-HSA-3700989)	360	0	1.89	-	 < 0.01	2.69E-01	1.00E00
Biosynthesis of DPAn-3-derived protectins and resolvins (R-HSA-9026286)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Signaling by MET (R-HSA-6806834)	77	0	.40	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of Cell Cycle Genes (R-HSA-6791312)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
Signaling by Ligand-Responsive EGFR Variants in Cancer (R-HSA-5637815)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of Death Receptors and Ligands (R-HSA-6803211)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) (R-HSA-5358565)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective MPI causes MPI-CDG (CDG-1b) (R-HSA-4043916)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Signaling by EGFRvIII in Cancer (R-HSA-5637812)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Constitutive Signaling by EGFRvIII (R-HSA-5637810)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Defective PMM2 causes PMM2-CDG (CDG-1a) (R-HSA-4043911)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Formation of tubulin folding intermediates by CCT/TriC (R-HSA-389960)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
DARPP-32 events (R-HSA-180024)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
Growth hormone receptor signaling (R-HSA-982772)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Interaction between PHLDA1 and AURKA (R-HSA-8854521)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Calcitonin-like ligand receptors (R-HSA-419812)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
p75 NTR receptor-mediated signalling (R-HSA-193704)	98	0	.51	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of Caspase Activators and Caspases (R-HSA-6803207)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain (R-HSA-6803205)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release (R-HSA-6803204)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Sema4D mediated inhibition of cell attachment and migration (R-HSA-416550)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Molybdenum cofactor biosynthesis (R-HSA-947581)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding (R-HSA-389958)	32	0	.17	-	 < 0.01	1.00E00	1.00E00
Diseases associated with surfactant metabolism (R-HSA-5687613)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Prefoldin mediated transfer of substrate  to CCT/TriC (R-HSA-389957)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate (R-HSA-2978092)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
mRNA 3'-end processing (R-HSA-72187)	57	0	.30	-	 < 0.01	1.00E00	1.00E00
SMAD2/3 MH2 Domain Mutants in Cancer (R-HSA-3315487)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Activation of NMDA receptor and postsynaptic events (R-HSA-442755)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
AURKA Activation by TPX2 (R-HSA-8854518)	71	0	.37	-	 < 0.01	1.00E00	1.00E00
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) (R-HSA-975957)	115	0	.60	-	 < 0.01	1.00E00	1.00E00
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) (R-HSA-975956)	95	0	.50	-	 < 0.01	1.00E00	1.00E00
PD-1 signaling (R-HSA-389948)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation (R-HSA-8869496)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
CDO in myogenesis (R-HSA-375170)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Defective NEU1 causes sialidosis (R-HSA-4341670)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Regulation of FZD by ubiquitination (R-HSA-4641263)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Disassembly of the destruction complex and recruitment of AXIN to the membrane (R-HSA-4641262)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
mRNA Splicing (R-HSA-72172)	188	0	.98	-	 < 0.01	1.00E00	1.00E00
Activation of CaMK IV (R-HSA-442745)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
CREB phosphorylation through the activation of Ras (R-HSA-442742)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Metabolism of steroid hormones (R-HSA-196071)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
Defective RFT1 causes RFT1-CDG (CDG-1n) (R-HSA-4570571)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
DDX58/IFIH1-mediated induction of interferon-alpha/beta (R-HSA-168928)	77	0	.40	-	 < 0.01	1.00E00	1.00E00
TICAM1, RIP1-mediated IKK complex recruitment  (R-HSA-168927)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
RUNX2 regulates genes involved in differentiation of myeloid cells (R-HSA-8941333)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
RUNX2 regulates genes involved in cell migration (R-HSA-8941332)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Interconversion of polyamines (R-HSA-351200)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Intra-Golgi traffic (R-HSA-6811438)	43	0	.23	-	 < 0.01	1.00E00	1.00E00
Ion influx/efflux at host-pathogen interface (R-HSA-6803544)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
NCAM signaling for neurite out-growth (R-HSA-375165)	60	0	.31	-	 < 0.01	1.00E00	1.00E00
COPI-independent Golgi-to-ER retrograde traffic (R-HSA-6811436)	52	0	.27	-	 < 0.01	1.00E00	1.00E00
Fibronectin matrix formation (R-HSA-1566977)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
COPI-dependent Golgi-to-ER retrograde traffic (R-HSA-6811434)	100	0	.52	-	 < 0.01	1.00E00	1.00E00
Interferon Signaling (R-HSA-913531)	193	0	1.01	-	 < 0.01	6.29E-01	1.00E00
mRNA Splicing - Minor Pathway (R-HSA-72165)	52	0	.27	-	 < 0.01	1.00E00	1.00E00
Meiotic recombination (R-HSA-912446)	56	0	.29	-	 < 0.01	1.00E00	1.00E00
Receptor-type tyrosine-protein phosphatases (R-HSA-388844)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
mRNA Splicing - Major Pathway (R-HSA-72163)	180	0	.94	-	 < 0.01	1.00E00	1.00E00
Adenosine P1 receptors (R-HSA-417973)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
MAPK3 (ERK1) activation (R-HSA-110056)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
eNOS activation and regulation (R-HSA-203765)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
RUNX2 regulates bone development (R-HSA-8941326)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Assembly of the ORC complex at the origin of replication (R-HSA-68616)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) (R-HSA-5660724)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Toll Like Receptor 2 (TLR2) Cascade (R-HSA-181438)	97	0	.51	-	 < 0.01	1.00E00	1.00E00
RUNX1 regulates expression of components of tight junctions (R-HSA-8935964)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Adrenaline signalling through Alpha-2 adrenergic receptor (R-HSA-392023)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
The proton buffering model (R-HSA-167827)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
The fatty acid cycling model (R-HSA-167826)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
SUMO is proteolytically processed (R-HSA-3065679)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
SUMO is transferred from E1 to E2 (UBE2I, UBC9) (R-HSA-3065678)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Interleukin-21 signaling (R-HSA-9020958)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
ERKs are inactivated (R-HSA-202670)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
SUMO is conjugated to E1 (UBA2:SAE1) (R-HSA-3065676)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Acetylcholine binding and downstream events (R-HSA-181431)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Interleukin-27 signaling (R-HSA-9020956)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
BMAL1:CLOCK,NPAS2 activates circadian gene expression (R-HSA-1368108)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Norepinephrine Neurotransmitter Release Cycle (R-HSA-181430)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
IRF3-mediated induction of type I IFN (R-HSA-3270619)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
CREB phosphorylation through the activation of CaMKII (R-HSA-442729)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
snRNP Assembly (R-HSA-191859)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) (R-HSA-5658471)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
p38MAPK events (R-HSA-171007)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
CREB phosphorylation through the activation of Adenylate Cyclase (R-HSA-442720)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
NOSIP mediated eNOS trafficking (R-HSA-203754)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Lysine catabolism (R-HSA-71064)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
FGFR2 alternative splicing (R-HSA-6803529)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
TNFR1-mediated ceramide production (R-HSA-5626978)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Organic anion transport (R-HSA-561048)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Serotonin Neurotransmitter Release Cycle (R-HSA-181429)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Activation of the pre-replicative complex (R-HSA-68962)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 (R-HSA-5625886)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
P2Y receptors (R-HSA-417957)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
TNFR1-induced proapoptotic signaling (R-HSA-5357786)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
SHC1 events in EGFR signaling (R-HSA-180336)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
CREB phosphorylation through the activation of CaMKK (R-HSA-442717)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) (R-HSA-2162123)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
KSRP (KHSRP) binds and destabilizes mRNA (R-HSA-450604)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
CYP2E1 reactions (R-HSA-211999)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
GP1b-IX-V activation signalling (R-HSA-430116)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Sterols are 12-hydroxylated by CYP8B1 (R-HSA-211994)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Mismatch Repair (R-HSA-5358508)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Antagonism of Activin by Follistatin (R-HSA-2473224)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Ligand-receptor interactions (R-HSA-5632681)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Elastic fibre formation (R-HSA-1566948)	45	0	.24	-	 < 0.01	1.00E00	1.00E00
DNA replication initiation (R-HSA-68952)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Glycogen metabolism (R-HSA-8982491)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Interleukin-23 signaling (R-HSA-9020933)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
EGFR interacts with phospholipase C-gamma (R-HSA-212718)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
APOBEC3G mediated resistance to HIV-1 infection (R-HSA-180689)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Apoptotic factor-mediated response (R-HSA-111471)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
MET activates PTK2 signaling (R-HSA-8874081)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of maresin-like SPMs (R-HSA-9027307)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
EPH-ephrin mediated repulsion of cells (R-HSA-3928665)	50	0	.26	-	 < 0.01	1.00E00	1.00E00
Ephrin signaling (R-HSA-3928664)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
EPHA-mediated growth cone collapse (R-HSA-3928663)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Diseases of carbohydrate metabolism (R-HSA-5663084)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
FMO oxidises nucleophiles (R-HSA-217271)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
EPHB-mediated forward signaling (R-HSA-3928662)	41	0	.21	-	 < 0.01	1.00E00	1.00E00
Resolution of AP sites via the single-nucleotide replacement pathway (R-HSA-110381)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of DPA-derived SPMs (R-HSA-9018683)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of maresins (R-HSA-9018682)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
PI3K/AKT activation (R-HSA-198203)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of protectins (R-HSA-9018681)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Xenobiotics (R-HSA-211981)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Intestinal saccharidase deficiencies (R-HSA-5659898)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
SUMOylation of ubiquitinylation proteins (R-HSA-3232142)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
SMAC-mediated apoptotic response (R-HSA-111469)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Apoptotic cleavage of cellular proteins (R-HSA-111465)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
TRIF-mediated programmed cell death (R-HSA-2562578)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Caspase activation via extrinsic apoptotic signalling pathway (R-HSA-5357769)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
SMAC-mediated dissociation of IAP:caspase complexes  (R-HSA-111464)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
SMAC binds to IAPs  (R-HSA-111463)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Cytochrome c-mediated apoptotic response (R-HSA-111461)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Metabolism of cofactors (R-HSA-8978934)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Formation of annular gap junctions (R-HSA-196025)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of EPA-derived SPMs (R-HSA-9018679)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Eicosanoids (R-HSA-211979)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Resolution of AP sites via the multiple-nucleotide patch replacement pathway (R-HSA-110373)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of specialized proresolving mediators (SPMs) (R-HSA-9018678)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of DHA-derived SPMs (R-HSA-9018677)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Ion homeostasis (R-HSA-5578775)	54	0	.28	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of D-series resolvins (R-HSA-9018676)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Endogenous sterols (R-HSA-211976)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Defective ABCA1 causes Tangier disease (R-HSA-5682113)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Propionyl-CoA catabolism (R-HSA-71032)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
TRKA activation by NGF (R-HSA-187042)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Metabolism of nucleotides (R-HSA-15869)	94	0	.49	-	 < 0.01	1.00E00	1.00E00
Activation of Nicotinic Acetylcholine Receptors (R-HSA-629602)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Activation of caspases through apoptosome-mediated cleavage (R-HSA-111459)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Tight junction interactions (R-HSA-420029)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Formation of apoptosome (R-HSA-111458)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Plus-strand DNA synthesis (R-HSA-164525)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Release of apoptotic factors from the mitochondria (R-HSA-111457)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
vRNP Assembly (R-HSA-192905)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Activated NTRK2 signals through FRS2 and FRS3 (R-HSA-9028731)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members (R-HSA-111453)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate (R-HSA-880009)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Activation and oligomerization of BAK protein (R-HSA-111452)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Protein folding (R-HSA-391251)	100	0	.52	-	 < 0.01	1.00E00	1.00E00
N-glycan trimming and elongation in the cis-Golgi (R-HSA-964739)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Physiological factors (R-HSA-5578768)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
trans-Golgi Network Vesicle Budding (R-HSA-199992)	72	0	.38	-	 < 0.01	1.00E00	1.00E00
Signaling by NTRK1 (TRKA) (R-HSA-187037)	76	0	.40	-	 < 0.01	1.00E00	1.00E00
POLB-Dependent Long Patch Base Excision Repair (R-HSA-110362)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Presynaptic phase of homologous DNA pairing and strand exchange (R-HSA-5693616)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Ethanol oxidation (R-HSA-71384)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
NOTCH2 intracellular domain regulates transcription (R-HSA-2197563)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
ATF6 (ATF6-alpha) activates chaperone genes (R-HSA-381183)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Alpha-defensins (R-HSA-1462054)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
TET1,2,3 and TDG demethylate DNA (R-HSA-5221030)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Minus-strand DNA synthesis (R-HSA-164516)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Activation of NOXA and translocation to mitochondria (R-HSA-111448)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of DPAn-6 SPMs (R-HSA-9025106)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Cellular hexose transport (R-HSA-189200)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
Activation of BAD and translocation to mitochondria  (R-HSA-111447)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Activation of BIM and translocation to mitochondria  (R-HSA-111446)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Tachykinin receptors bind tachykinins (R-HSA-380095)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Intestinal hexose absorption (R-HSA-8981373)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Telomere Extension By Telomerase (R-HSA-171319)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Displacement of DNA glycosylase by APEX1 (R-HSA-110357)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Miscellaneous substrates (R-HSA-211958)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 (R-HSA-211957)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Processing of DNA double-strand break ends (R-HSA-5693607)	81	0	.42	-	 < 0.01	1.00E00	1.00E00
NGF-independant TRKA activation (R-HSA-187024)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
DNA Double Strand Break Response (R-HSA-5693606)	60	0	.31	-	 < 0.01	1.00E00	1.00E00
SUMOylation of transcription factors (R-HSA-3232118)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Synthesis of dolichyl-phosphate mannose (R-HSA-162699)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
G2 Phase (R-HSA-68911)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
VEGFR2 mediated cell proliferation (R-HSA-5218921)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Activated NTRK3 signals through PLCG1 (R-HSA-9034793)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
VEGFR2 mediated vascular permeability (R-HSA-5218920)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
Defective ALG12 causes ALG12-CDG (CDG-1g) (R-HSA-4720489)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Transcriptional regulation by small RNAs (R-HSA-5578749)	72	0	.38	-	 < 0.01	1.00E00	1.00E00
Packaging Of Telomere Ends (R-HSA-171306)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Interleukin-3, Interleukin-5 and GM-CSF signaling (R-HSA-512988)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
Activation of TRKA receptors (R-HSA-187015)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Phase I - Functionalization of compounds (R-HSA-211945)	105	0	.55	-	 < 0.01	1.00E00	1.00E00
Defective ABCC6 causes pseudoxanthoma elasticum (PXE) (R-HSA-5690338)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Dectin-2 family (R-HSA-5621480)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Oligomerization of connexins into connexons (R-HSA-190704)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Metabolism of steroids (R-HSA-8957322)	147	0	.77	-	 < 0.01	1.00E00	1.00E00
Negative regulation of TCF-dependent signaling by WNT ligand antagonists (R-HSA-3772470)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Acyl chain remodeling of DAG and TAG (R-HSA-1482883)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
DNA Damage Bypass (R-HSA-73893)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
Defective PAPSS2 causes SEMD-PA (R-HSA-3560796)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective ALG3 causes ALG3-CDG (CDG-1d) (R-HSA-4720475)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC26A2 causes chondrodysplasias (R-HSA-3560792)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
PP2A-mediated dephosphorylation of key metabolic factors (R-HSA-163767)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Import of palmitoyl-CoA into the mitochondrial matrix (R-HSA-200425)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Cleavage of the damaged purine (R-HSA-110331)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Recognition and association of DNA glycosylase with site containing an affected purine (R-HSA-110330)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Fatty acids (R-HSA-211935)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Defective Mismatch Repair Associated With PMS2 (R-HSA-5632987)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective DOLK causes DOLK-CDG (CDG-1m) (R-HSA-4755583)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Activated NTRK2 signals through PLCG1 (R-HSA-9026527)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Pyruvate metabolism (R-HSA-70268)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Death Receptor Signalling (R-HSA-73887)	141	0	.74	-	 < 0.01	1.00E00	1.00E00
Chromosome Maintenance (R-HSA-73886)	90	0	.47	-	 < 0.01	1.00E00	1.00E00
Base Excision Repair (R-HSA-73884)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
CASP8 activity is inhibited (R-HSA-5218900)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Gluconeogenesis (R-HSA-70263)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
2-LTR circle formation (R-HSA-164843)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective B4GALT7 causes EDS, progeroid type (R-HSA-3560783)	20	0	.10	-	 < 0.01	1.00E00	1.00E00
SHC1 events in ERBB4 signaling (R-HSA-1250347)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Diseases associated with glycosaminoglycan metabolism (R-HSA-3560782)	41	0	.21	-	 < 0.01	1.00E00	1.00E00
Cleavage of the damaged pyrimidine  (R-HSA-110329)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Recognition and association of DNA glycosylase with site containing an affected pyrimidine (R-HSA-110328)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of A2E, implicated in retinal degradation (R-HSA-2466712)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
PI3K events in ERBB4 signaling (R-HSA-1250342)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Biosynthesis of electrophilic ?-3 PUFA oxo-derivatives (R-HSA-9027604)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Insulin effects increased synthesis of Xylulose-5-Phosphate (R-HSA-163754)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ (R-HSA-4755579)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of PIPs at the late endosome membrane (R-HSA-1660517)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Defective ABCG5 causes sitosterolemia (R-HSA-5679096)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F) (R-HSA-5663020)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Synthesis of PIPs at the early endosome membrane (R-HSA-1660516)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Chondroitin sulfate biosynthesis (R-HSA-2022870)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Synthesis of PIPs at the Golgi membrane (R-HSA-1660514)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Activated NTRK2 signals through RAS (R-HSA-9026519)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Translesion Synthesis by POLH (R-HSA-110320)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia (R-HSA-5679090)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Translocation of SLC2A4 (GLUT4) to the plasma membrane (R-HSA-1445148)	71	0	.37	-	 < 0.01	1.00E00	1.00E00
RIPK1-mediated regulated necrosis (R-HSA-5213460)	19	0	.10	-	 < 0.01	1.00E00	1.00E00
SMAD4 MH2 Domain Mutants in Cancer (R-HSA-3311021)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Sphingolipid metabolism (R-HSA-428157)	87	0	.46	-	 < 0.01	1.00E00	1.00E00
Defective ALG9 causes ALG9-CDG (CDG-1l) (R-HSA-4720454)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Polymerase switching (R-HSA-69091)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane (R-HSA-83936)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Recognition of DNA damage by PCNA-containing replication complex (R-HSA-110314)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template (R-HSA-110313)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
Translesion synthesis by REV1 (R-HSA-110312)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
alpha-linolenic acid (ALA) metabolism (R-HSA-2046106)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Linoleic acid (LA) metabolism (R-HSA-2046105)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
MGMT-mediated DNA damage reversal (R-HSA-5657655)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Pentose phosphate pathway (R-HSA-71336)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Rab regulation of trafficking (R-HSA-9007101)	121	0	.63	-	 < 0.01	1.00E00	1.00E00
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism (R-HSA-2046104)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Vitamins (R-HSA-211916)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Defective Mismatch Repair Associated With MSH6 (R-HSA-5632968)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Type I hemidesmosome assembly (R-HSA-446107)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Golgi Cisternae Pericentriolar Stack Reorganization (R-HSA-162658)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Association of TriC/CCT with target proteins during biosynthesis (R-HSA-390471)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Inositol transporters (R-HSA-429593)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase I Transcription (R-HSA-73864)	80	0	.42	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase I Transcription Termination (R-HSA-73863)	31	0	.16	-	 < 0.01	1.00E00	1.00E00
Vitamin E (R-HSA-8877627)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Transcription-Coupled Nucleotide Excision Repair (TC-NER) (R-HSA-6781827)	78	0	.41	-	 < 0.01	1.00E00	1.00E00
FCERI mediated MAPK activation (R-HSA-2871796)	90	0	.47	-	 < 0.01	1.00E00	1.00E00
Keratan sulfate degradation (R-HSA-2022857)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
Phase 1 - inactivation of fast Na+ channels (R-HSA-5576894)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Formation of TC-NER Pre-Incision Complex (R-HSA-6781823)	53	0	.28	-	 < 0.01	1.00E00	1.00E00
Phase 0 - rapid depolarisation (R-HSA-5576892)	44	0	.23	-	 < 0.01	1.00E00	1.00E00
Keratan sulfate biosynthesis (R-HSA-2022854)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
GRB2:SOS provides linkage to MAPK signaling for Integrins  (R-HSA-354194)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Activation of ATR in response to replication stress (R-HSA-176187)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
Chaperonin-mediated protein folding (R-HSA-390466)	94	0	.49	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II Transcription Termination (R-HSA-73856)	66	0	.35	-	 < 0.01	1.00E00	1.00E00
Signaling by VEGF (R-HSA-194138)	104	0	.54	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase I Promoter Clearance (R-HSA-73854)	78	0	.41	-	 < 0.01	1.00E00	1.00E00
Defective HLCS causes multiple carboxylase deficiency (R-HSA-3371599)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective BTD causes biotidinase deficiency (R-HSA-3371598)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) (R-HSA-5661182)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
RHO GTPases regulate CFTR trafficking (R-HSA-5627083)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Androgen biosynthesis (R-HSA-193048)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
RIP-mediated NFkB activation via ZBP1 (R-HSA-1810476)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Eukaryotic Translation Termination (R-HSA-72764)	93	0	.49	-	 < 0.01	1.00E00	1.00E00
CREB phosphorylation (R-HSA-199920)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Acyl chain remodelling of PE (R-HSA-1482839)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Signalling to ERKs (R-HSA-187687)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Folding of actin by CCT/TriC (R-HSA-390450)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Aryl hydrocarbon receptor signalling (R-HSA-8937144)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
MET activates STAT3 (R-HSA-8875791)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
5-Phosphoribose 1-diphosphate biosynthesis (R-HSA-73843)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Glycogen breakdown (glycogenolysis) (R-HSA-70221)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
tRNA modification in the mitochondrion (R-HSA-6787450)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3) (R-HSA-5688399)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Constitutive Signaling by NOTCH1 HD Domain Mutants (R-HSA-2691232)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Signaling by NOTCH1 HD Domain Mutants in Cancer (R-HSA-2691230)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
Influenza Virus Induced Apoptosis (R-HSA-168277)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS) (R-HSA-5688031)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
NS1 Mediated Effects on Host Pathways (R-HSA-168276)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant (R-HSA-2660826)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant (R-HSA-2660825)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
Entry of Influenza Virion into Host Cell via Endocytosis (R-HSA-168275)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Export of Viral Ribonucleoproteins from Nucleus (R-HSA-168274)	29	0	.15	-	 < 0.01	1.00E00	1.00E00
Kinesins (R-HSA-983189)	61	0	.32	-	 < 0.01	1.00E00	1.00E00
Transport of Ribonucleoproteins into the Host Nucleus (R-HSA-168271)	28	0	.15	-	 < 0.01	1.00E00	1.00E00
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling (R-HSA-5339717)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Misspliced GSK3beta mutants stabilize beta-catenin (R-HSA-5339716)	15	0	.08	-	 < 0.01	1.00E00	1.00E00
NTRK3 as a dependence receptor (R-HSA-9603505)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
SUMOylation of DNA damage response and repair proteins (R-HSA-3108214)	70	0	.37	-	 < 0.01	1.00E00	1.00E00
Peptide chain elongation (R-HSA-156902)	89	0	.47	-	 < 0.01	1.00E00	1.00E00
Surfactant metabolism (R-HSA-5683826)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
Interactions of Rev with host cellular proteins (R-HSA-177243)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Virus Assembly and Release (R-HSA-168268)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Heparan sulfate/heparin (HS-GAG) metabolism (R-HSA-1638091)	55	0	.29	-	 < 0.01	1.00E00	1.00E00
HSF1-dependent transactivation (R-HSA-3371571)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
RSK activation (R-HSA-444257)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression (R-HSA-427389)	45	0	.24	-	 < 0.01	1.00E00	1.00E00
Defective Mismatch Repair Associated With MSH2 (R-HSA-5632928)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Defective Mismatch Repair Associated With MSH3 (R-HSA-5632927)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
Antigen Presentation: Folding, assembly and peptide loading of class I MHC (R-HSA-983170)	26	0	.14	-	 < 0.01	1.00E00	1.00E00
Transcription of the HIV genome (R-HSA-167172)	73	0	.38	-	 < 0.01	1.00E00	1.00E00
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors (R-HSA-8864260)	36	0	.19	-	 < 0.01	1.00E00	1.00E00
Attenuation phase (R-HSA-3371568)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Activation of PPARGC1A (PGC-1alpha) by phosphorylation (R-HSA-2151209)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) (R-HSA-5655799)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Cap-dependent Translation Initiation (R-HSA-72737)	119	0	.62	-	 < 0.01	1.00E00	1.00E00
APC-Cdc20 mediated degradation of Nek2A (R-HSA-179409)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
Transcriptional activation of mitochondrial biogenesis (R-HSA-2151201)	53	0	.28	-	 < 0.01	1.00E00	1.00E00
Recycling of eIF2:GDP (R-HSA-72731)	8	0	.04	-	 < 0.01	1.00E00	1.00E00
Host Interactions with Influenza Factors (R-HSA-168253)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
MET activates RAS signaling (R-HSA-8851805)	9	0	.05	-	 < 0.01	1.00E00	1.00E00
Nucleotide-like (purinergic) receptors (R-HSA-418038)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
HIV Transcription Elongation (R-HSA-167169)	46	0	.24	-	 < 0.01	1.00E00	1.00E00
SUMOylation of immune response proteins (R-HSA-4755510)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
GABA B receptor activation (R-HSA-977444)	39	0	.20	-	 < 0.01	1.00E00	1.00E00
RNA Polymerase II HIV Promoter Escape (R-HSA-167162)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
GABA receptor activation (R-HSA-977443)	55	0	.29	-	 < 0.01	1.00E00	1.00E00
Acyl chain remodelling of PS (R-HSA-1482801)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
HIV Transcription Initiation (R-HSA-167161)	47	0	.25	-	 < 0.01	1.00E00	1.00E00
GABA A (rho) receptor activation (R-HSA-977442)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Purine ribonucleoside monophosphate biosynthesis (R-HSA-73817)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
GABA A receptor activation (R-HSA-977441)	13	0	.07	-	 < 0.01	1.00E00	1.00E00
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection (R-HSA-167160)	27	0	.14	-	 < 0.01	1.00E00	1.00E00
VLDLR internalisation and degradation (R-HSA-8866427)	12	0	.06	-	 < 0.01	1.00E00	1.00E00
Mitochondrial translation (R-HSA-5368287)	94	0	.49	-	 < 0.01	1.00E00	1.00E00
VLDL assembly (R-HSA-8866423)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
Mitochondrial translation initiation (R-HSA-5368286)	88	0	.46	-	 < 0.01	1.00E00	1.00E00
Cellular response to heat stress (R-HSA-3371556)	87	0	.46	-	 < 0.01	1.00E00	1.00E00
Activation of the phototransduction cascade (R-HSA-2485179)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Mitochondrial Fatty Acid Beta-Oxidation (R-HSA-77289)	38	0	.20	-	 < 0.01	1.00E00	1.00E00
Keratan sulfate/keratin metabolism (R-HSA-1638074)	34	0	.18	-	 < 0.01	1.00E00	1.00E00
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids (R-HSA-77288)	6	0	.03	-	 < 0.01	1.00E00	1.00E00
Diseases associated with the TLR signaling cascade (R-HSA-5602358)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
mitochondrial fatty acid beta-oxidation of saturated fatty acids (R-HSA-77286)	11	0	.06	-	 < 0.01	1.00E00	1.00E00
Beta oxidation of myristoyl-CoA to lauroyl-CoA (R-HSA-77285)	3	0	.02	-	 < 0.01	1.00E00	1.00E00
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol (R-HSA-193368)	23	0	.12	-	 < 0.01	1.00E00	1.00E00
Tandem pore domain halothane-inhibited K+ channel (THIK) (R-HSA-1299287)	1	0	.01	-	 < 0.01	1.00E00	1.00E00
Vpr-mediated nuclear import of PICs (R-HSA-180910)	30	0	.16	-	 < 0.01	1.00E00	1.00E00
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway (R-HSA-5649702)	7	0	.04	-	 < 0.01	1.00E00	1.00E00
SHC-mediated cascade:FGFR2 (R-HSA-5654699)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Intestinal absorption (R-HSA-8963676)	4	0	.02	-	 < 0.01	1.00E00	1.00E00
Downstream signaling of activated FGFR2 (R-HSA-5654696)	24	0	.13	-	 < 0.01	1.00E00	1.00E00
PI-3K cascade:FGFR2 (R-HSA-5654695)	18	0	.09	-	 < 0.01	1.00E00	1.00E00
Formation of the HIV-1 Early Elongation Complex (R-HSA-167158)	33	0	.17	-	 < 0.01	1.00E00	1.00E00
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon (R-HSA-936964)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
FRS-mediated FGFR1 signaling (R-HSA-5654693)	17	0	.09	-	 < 0.01	1.00E00	1.00E00
Presynaptic function of Kainate receptors (R-HSA-500657)	21	0	.11	-	 < 0.01	1.00E00	1.00E00
MASTL Facilitates Mitotic Progression (R-HSA-2465910)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
Formation of HIV elongation complex in the absence of HIV Tat (R-HSA-167152)	48	0	.25	-	 < 0.01	1.00E00	1.00E00
Truncations of AMER1 destabilize the destruction complex (R-HSA-5467348)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Regulation of pyruvate dehydrogenase (PDH) complex (R-HSA-204174)	16	0	.08	-	 < 0.01	1.00E00	1.00E00
Thyroxine biosynthesis (R-HSA-209968)	10	0	.05	-	 < 0.01	1.00E00	1.00E00
AXIN missense mutants destabilize the destruction complex (R-HSA-5467340)	14	0	.07	-	 < 0.01	1.00E00	1.00E00
Metabolism of non-coding RNA (R-HSA-194441)	49	0	.26	-	 < 0.01	1.00E00	1.00E00
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS) (R-HSA-5688354)	2	0	.01	-	 < 0.01	1.00E00	1.00E00
SIRT1 negatively regulates rRNA expression (R-HSA-427359)	37	0	.19	-	 < 0.01	1.00E00	1.00E00
RUNX3 regulates BCL2L11 (BIM) transcription (R-HSA-8952158)	5	0	.03	-	 < 0.01	1.00E00	1.00E00
HS-GAG degradation (R-HSA-2024096)	22	0	.12	-	 < 0.01	1.00E00	1.00E00
O-linked glycosylation (R-HSA-5173105)	114	0	.60	-	 < 0.01	1.00E00	1.00E00
Interleukin-7 signaling (R-HSA-1266695)	25	0	.13	-	 < 0.01	1.00E00	1.00E00
